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1. Introduction 
1.1 Epidemiology: 
 
As urothelial cancer is a cancer of the environment and age, the incidence and 
prevalence rates increase with age and associated with environmental toxins1.  
According to the American Cancer Society statistics, there were 68,810 total 
cases diagnosed with bladder cancer (51,230 men and 17.580 women) accounting 
for 7% of all cancers1. By contrast in Europe 104,400 incident cases were diagnosed 
in 2006, (82,800 in men and 21,600 in women) which represents 6.6 % and 2.1 % of 
all cancer cases for men and women, respectively2. In men, bladder cancer is the 
fourth most common cancer and accounts for 4.1% of total cancer deaths in men and 
1.8% of total cancer deaths in women2. 
There is a geographic difference in the incidence around the world. The 
highest rates are reported in Southern and Eastern Europe, North Africa, the Middle 
East, and North America whereas the lowest are reported in Asia and 
underdeveloped areas of Africa2. In 2002 bladder cancer was the 9th most common 
cancer worldwide and the 13th most common cause of death worldwide3. The 
histologic cell type of bladder cancer varies also geographically. In North America 
and Europe, 95% to 97% of all cases are urothelial cell carcinoma; by contrast in 
Africa 60% to 90% are urothelial and 10% to 40% are squamous cell cancer cases. 
Egypt has the highest rate of squamous cell carcinoma due to the endemic infections 
with Schistosoma species. The mortality rate in Egypt is 3 times higher than in 
Europe and 8 times greater than in North America possibly due to higher tumour 
aggressiveness of squamous cell carcinoma that is highly prevalent in Egypt3. 
 
1.2 Diagnosis and Staging: 
1.2.1 Diagniosis: 
EAU guidelines recommended doing cystoscopy with biopsy for urological 
diagnosis of invasive bladder cancer, Imaging only if staging will make a difference to 
the selection of treatment options and local staging for patients considered suitable 
for radical treatment either magnetic resonance imaging with fast dynamic contrast 
enhancement or multidetector-row CT with contrast enhancement. 
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For patients with confirmed muscle-invasive bladder cancer multidetector-row 
CT of the chest, abdomen and pelvis, including multidetector-row urography for 
complete examination of the upper urinary tracts are recommended. Lesser 
alternatives (e.g. if multidetector-row CT is unavailable) are excretory urography and 
a chest X-ray4. 
 
1.2.2 Staging: 
TNM classification of urinary bladder cancer is described in table (1) 
 
T - Primary tumour 
 
   
 TX  Primary tumour cannot be assessed 
 T0   No evidence of primary tumour 
 Ta  Non-invasive papillary carcinoma 
 Tis  Carcinoma in situ: ‘flat tumour’ 
 T1  Tumour invades subepithelial connective 
tissue 
 T2  Tumour invades muscle 
  T2a  Tumour invades superficial muscle (inner half) 
  T2b Tumour invades deep muscle (outer half) 
 T3   Tumour invades perivesical tissue 
  T3a Microscopically 
  T3b Macroscopically (extravesical mass) 
 T4   Tumour invades any of the following: prostate, 
uterus, vagina, pelvic wall, abdominal wall 
  T4a Tumour invades prostate, uterus or vagina 
  T4b Tumour invades pelvic wall or abdominal wall 
N - Lymph nodes    
 NX  Regional lymph nodes cannot be assessed 
 N0  No regional lymph node metastasis 
 N1  Metastasis in a single lymph node in the true 
pelvis (hypogastric, obturator, external iliac or 
presacral) 
 N2  Metastasis in multiple lymph nodes in the true 
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pelvis (hypogastric, obturator, external iliac or 
presacral) 
 N3   Metastasis in common iliac lymph node(s) 
M - Distant 
metastasis 
   
 M0   No distant metastasis 
 M1   Distant metastasis 
Table (1)    TNM classification of urinary bladder cancer5  
 
WHO grading 
The WHO grading (1998) for bladder cancer is shown in table (2) 
 
Grade 1 moderately differentiated 
Grade 2 well differentiated 
Grade 3 poorly differentiated 
Table (2)     The WHO grading(1998) for bladder cancer 6 
 
1.3 Radical cystectomy: 
1.3.1 Indications: 
Indications of radical cystectomy in bladder cancer patients include7 T2-T4a, 
N0 M0 BC as well as all T1 patients if failure of intravesical therapy, recurrences after 
bladder sparing treatments, non-urothelial carcinomas, high risk non-muscle-invasive 
BC (i.e. patients with multiple tumours, high grade tumours, associated CIS) 
 
1.3.2 Technique: 
Radical cystectomy includes the removal of the tumour bearing bladder and 
surrounding perivesical soft tissue, adjacent distal ureters as well as prostate, and 
seminal vesicles in men and the ovaries, uterus/cervix, and anterior vaginal wall in 
women8. It also includes the retrieval of bilateral pelvic lymph nodes the extent of 
which has not been clearly defined so far9. Although removal of bladder and lymph 
nodes are the integral parts of the procedure there is a big controversy about the 
radicality of the surgical approach. Chang et al recommended to spare the internal 
female organs because involvement of the uterus, cervix, and ovaries was found to 
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be uncommon10. Furthermore preservation of the vagina and uterus provides 
functional better support for the neobladder and the pelvic floor11. 
A standard lymphadenectomy in bladder cancer patients involves the removal 
of all nodal tissue cranially up to the cross of the common iliac bifurcation with the 
ureter being the medial border, laterally the genitofemoral nerves and caudally the 
lymph node of Cloquet12. An extended lymphadenectomy includes all lymph nodes in 
the region of the aortic bifurcation and common iliac vessels medially to the crossing 
ureters and including the internal iliac, presacral, obturator fossa and external iliac 
nodes9,13 .  
Roth et al used single-photon emission computed tomography (SPECT) 
combined with computed tomography (CT) plus intraoperative gamma and found that 
lymphadenectomy limited to the ventral portion of the external iliac vessels and 
obturator fossa removed only about 50% of all primary lymphatic landing sites, 
whereas extended lymphadenectomy along the major pelvic vessels, including the 
internal iliac, external iliac, obturator, and common iliac region up to the uretero-iliac 
crossing, removed about 90% of them14. 
Since many studies have not found a minimum number of lymph nodes to be 
removed for accurate staging and therapeutic value in bladder cancer and 
interindividual differences in the number of lymph nodes , it seems reasonable to 
concentrate on the anatomical extent of lymphadenectomy15. Koppie et al found no 
evidence for a minimum number of LNs sufficient for optimizing bladder cancer 
outcomes when a limited or extended pelvic LN dissection wass performed during 
RC, but the probability of survival continued to rise as the number of LNs removed 
increased16. 
Similarly Capitanio and colleagues indicated that removing 25 LNs might 
represent the lowest threshold for the extent of lymphadenectomy at RC17 . 
In an attempt to preserve potency some authors reported satisfactory results 
reaching 79 % potency rates without compromising oncological outcomes18. Rozet 
and his colleges considered that prostate sparing RC to be a good option in selected 
patients with improved continence and potency rates and comparable oncological 
outcomes for radical cystoprostatectomy after long term follow up of sixty months19. 
However recent studies have shown that even a potency sparing approach results in 
7.4% risk of incidental prostate cancer in the apex20. 
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Standard RC is done by open surgery. Laparoscopic cystectomy and pelvic 
lymphadenectomy (with or without robotic assistance), with extracorporeal 
construction of urinary diversion, is an option for surgical treatment in experienced 
hands7. 
 
1.3.3 Complications: 
Today, radical cystectomy is a procedure with an acceptable rate of 
perioperative morbidity and mortality. Improvements in surgical technique and 
anaesthesia as well as increased quality of perioperative care in recent years have 
resulted in reduced morbidity and shorter hospital stay21. The frequency of 
complications after RC varies in literature reaching up to 64% of cases22 . 
 
1.3.3.1 Classification: 
Early and late 
Early complications occur in a short, well-defined interval of 90 days after 
surgery whereas complications occurring later than 90 days are defined as being 
late. Long-term complications may develop decades later. For example a colorectal 
cancer may develop in patients with ureterosigmoidostoy 10 years postoperatively23.  
Primary and Secondary 
Primary complications are those directly attributable to the cystectomy, 
including digestive system complications, accidental punctures or lacerations, 
postoperative fistulas, hematomas, seromas, and nonhealing surgical wounds.  
Secondary complications are defined as those that occur distantly from the surgical 
field, in an organ system other than the urinary tract (such as cardiac, respiratory, 
urinary, vascular, and postoperative infectious complications) and that could occur 
with most types of surgery23.  
 
1.3.3.2 Grading of Complications: 
A recent evaluation revealed that the majority of series reporting RC morbidity 
did not use a formal complication reporting system, nor utilize grading systems other 
than to categorize complications as ‘major’ or ‘minor’. In addition many series did not 
account for comorbidities, and define complications which made comparison of series 
impossible. Thus standardised methods for reporting data on surgical complications 
or morbidity after RC are urgently needed24.  
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The Clavien system for classifying surgical complications that was originally 
developed in 199225 and modified by Dindo et al in 200426  represents nowadays the 
standard for reporting surgical complications27. 
The Clavien system (Table 3)classifies the severity of a complication, by the 
level of intervention required to deal with it25.  
Although this system is less suitable for the reporting of long-term, it has been 
used with increasing frequency since 2008 in urological community duo to its 
standardized and well validated structure28. 
 
Grade Definition 
Grade I Any deviation from normal course after surgery with no need for 
pharmacological, surgical, endoscopic, and radiological 
interventions.Allowed therapeutic regimens includes: antiemetics, 
antipyretics, analgesia, diuretics, electrolytes, physiotherapy. Examples 
include ileus. This grade also includes wound infections opened at the 
bedside 
Grade II Requiring pharmacological treatment with drugs other than allowed for 
grade I complications Total parenteral nutrition and blood transfusion 
also included 
Grade III Requiring surgical, endoscopic or radiological intervention 
IIIa Intervention not under general anaesthesia. Example radiologically 
guided aspiration of fluid 
IIIb Intervention under general anaesthesia.Return to theatre due to control 
bleeding or other complications 
Grade IV Life-threatening complication requiring intensive care management 
IVa Single organ dysfunction (including dialysis).   
IVb Multi-organ dysfunction.  
Grade V Death of a patient. 
 
Table (3)    The Clavien system for classification of surgical complications26. 
 
1.3.3.3 Risk factors for complications: 
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Two large studies have evaluated risk factors associated with complication 
after RC. The first study by Shabsigh et al included 1,142 patients performed by well 
trained urologists in the same centre 
Univariate analysis identified gender, prior pelvic radiotherapy, estimated 
blood loss, number of packed red blood cells or fibrin patches used, and American 
Society of Anesthesiologists (ASA) score as significant predictors of any grade of 
complication. After using multivariate analysis, only gender, ASA score and type of 
urinary diversion were significant predictors, while prior pelvic radiotherapy and age 
trended towards significance22. 
Another study conducted by Hautmann et al. reported complication rate of 
1,000 neobladder procedures at a tertiary academic referral center. Their univariate 
analysis showed that the incidence and severity of complications correlated 
significantly with age, tumor stage, ASA score and preoperative comorbidity23.  
 
1.3.4 Oncological outcomes after cystectomy: 
1.3.4.1 Pelvic recurrence: 
Pelvic recurrence of transitional cell carcinoma after RC is relatively infrequent 
but when it develops, the prognosis is poor23. In a large series of 1054 patients 
treated with radical cystectomy, the local recurrence rate was 7% after a median 
follow-up of 10 yr. Local recurrence rate was slightly higher in patients with nonorgan- 
confined node-negative disease and node-positive disease compared with organ-
confined node-negative disease (13%, 13%, and 6%, respectively)29.Therefore, the 
role of orthotopic bladder replacement in patients undergoing cystectomy for locally 
advanced or node positive bladder cancer is unclear. In these patients, there is a risk 
that local recurrence might cause mechanical or functional interference with the 
reservoir23. Most recurrences manifest during the first 24 months, and many are 
concentrated within 6 to 18 months after surgery30. 
There is no difference in the recurrence rate between patients undergoing 
orthotopic diversion and those undergoing heterotopic diversion31. 
 
1.3.4.2 Distant metastasis 
Distant recurrence is noted in approximately 50% of patients treated with 
cystectomy, and most often (80% to 90%), this occurs within 24 months. Risk factors 
that increase the probability of distant recurrence are nodal status and pathologic 
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tumour stage. The most common sites of recurrence are the lungs, liver, and 
bones30. 
 
 
1.3.4.3 Upper tract recurrence: 
Upper tract recurrence rates range between 2% to 9% in different cystectomy 
series and generally occurs 24 to 40 months after surgery. Risk factors that are 
associated with upper tract recurrence are patients with carcinoma in situ, urethral 
involvement and ureteral involvement31.  
Suspicion of an upper tract recurrence in neobladder patients not clearly 
visible on radiographic examinations or small superficial tumours amenable to 
endourologic treatment usually are a dilemma in the urological field. Access to the 
upper urinary tract for diagnostic and therapeutic purposes is usually not easy in 
neobladder patients because of many factors like an antireflux valve mechanism, a 
long afferent ileal segment, difficulties in localizing the ureteral neo-orifice(s) 
implanted end-to-side according to Nesbit, and/or ureteral kinking at the 
reimplanation site9,32.  
The development of smaller and flexible ureteroscopes has led to an increase 
use of retrograde endoscopy both for treatment as well as surveillance of upper 
urinary tract tumours33. 
 
1.3.4.4 Secondary urethral tumours: 
The incidence of urethral recurrence after radical cystectomy in men ranges 
from 0% to 18%, with a meta-analysis in 2002 reporting an incidence of 
8.1%9,32.Urethral recurrence after cystectomy seems to be dependent on type of 
urinary diversion and time interval34.Freeman and his colleges found that urethral 
recurrence was 5% in orthotopic neo-bladder patients versus 24% in the blind-ending 
urethra after heterotopic urinary diversion. Risk factors that are significantly 
associated with urethral recuurence after RC are prostatic involvement of urothelial 
carcinoma, tumour multifocality, and type of urinary diversion35. Early symptoms of 
secondary urethral tumors may include hematuria (microscopic or gross) and 
changes in urinary stream. However the detection of asymptomatic UR is associated 
with significantly lower stage disease and improved patient survival35. 
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Urethral recurrence occurs in 3% to 15% of women and is associated with 
tumor at the bladder neck30. However, because 50% of women with bladder neck 
and/or anterior vaginal wall involvement do not demonstrate tumor within the urethra, 
these patients can still be eligible for orthotopic diversion if urethral margins at frozen 
section are negative9,36. 
 
1.4 Survival after cystectomy: 
Construction of nomograms for survival prediction had been performed by 
several groups. The principle advantage of this approach is that it provides a survival 
probability for individual cases with different predictive indices accuracy reaching up 
to 83.4%. This enables the clinicians to make the best decision in patient counselling, 
selecting the optimal adjuvant therapy and follow up schedule37-41. Outcome is best 
characterized by disease-specific survival versus overall survival, which 
underestimates the impact of treatment in patients with favourable tumor and nodal 
stage. 
In a large multicentre study a higher final pathological tumor stage, 
lymphovascular invasion, lymph node metastasis, adjuvant radiotherapy and 
adjuvant systemic chemotherapy were independently associated with recurrence free 
survival. Increasing patient age, higher final pathological tumor stage, 
lymphovascular invasion, lymph node metastasis and adjuvant radiotherapy were 
independently associated with cancer specific survival42.  
The largest single centre study up to date showed that the 5- and 10-yr RFS 
for patients with organ-confined, lymph node–negative tumours were 85% and 82%, 
respectively, and OS at 5 and 10 yr was 78% and 56%, respectively. The 5- and 10-
yr RFS and OS for patients with non–organ-confined, lymph node– negative tumours 
was 58% and 55%, respectively, and 47% and 27%, respectively29.  
Some evidence suggests that elevated preoperative serum CRP and presence 
of thrombocytosis are associated with decreased survival outcomes9,43,44. 
 
1.5 Quality of life after cystectomy: 
Several questionnaires have been validated for assessing health related 
quality of life (HRQoL) in patients with bladder cancer, including FACT (Functional 
Assessment of Cancer Therapy)-G45, EORTC QLQ-C3046, EORTC QLQ-BLM 
(muscle invasive bladder cancer module)47, SF (Short Form)-3648 and recently the 
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bladder cancer index (BCI) questionnaire specifically designed and validated for 
bladder cancer patients49. 
After careful analysis of all the QoL studies, it becomes evident there is a lack 
of good data evaluating QoL in patients with OBS versus other diversions. Most QoL 
studies used inappropriate questionnaires. Although some are validated, they were 
not designed to evaluate specific urologic aspects but rather QoL of patients during 
chemotherapy36. 
Published evidence does not support an advantage of one type of 
reconstruction over the others with regard to QOL. An important proposed reason for 
this is that patients are subjected preoperatively to method-to-patient matching, and 
thus are prepared for disadvantages associated with different methods34. 
Randomized prospective trials using well-validated disease-specific health-related 
QoL outcome instruments are warranted to render definitive conclusions regarding 
QoL measures with different type of diversions36. 
 
1.6 Urinary diversion: 
1.6.1 Types 
Fig. (1) Types of urinary diversion 
 
Urinary diversion 
Abdominal diversion 
Continent 
Continent  cutaneous 
catheterizable 
reservoirs 
Incontinent 
Ureterocutaneostomy Ileal conduit 
Urethral diversion 
Ortotopic 
 neobladder  
Rectosigmoid 
diversions 
Ureterocolonic 
 diversion 
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The choice of the urinary diversion after cystectomy depends on many factors 
both cancer-related (tumour stage) and patient-related factors. The latter includes the 
patient’s general health and social circumstances, baseline renal function, presence 
of a functional urethra, manual dexterity, and previous treatments including pelvic 
radiation, prostate surgery, or bowel resection. The ability of the patient to manage 
the diversion can only be judged by personal experience while talking to him, taking 
into account his social status and his capability to eventually perform a clean 
intermittent catheterization50,51. 
The current status of distribution of various urinary diversions after cystectomy 
for bladder cancer reflects a report of Hautmann and coworkers evaluating > 7000 
patients: neobladder, 47%; conduit, 33%; anal diversion, 10%; continent cutaneous 
diversion, 8%; and incontinent cutaneous diversion, 2% (fig.1)34. 
 
1.6.1.1 Ureterocutaneostomy 
Technically either one ureter to which the other shorter one is attached end-to-
side is connected to the skin (transuretero-ureterocutaneostomy) or both ureters are 
directly anastomosed to the skin52. 
Ureteral diversion to the abdominal wall is the simplest form of cutaneous 
diversion. It is considered as a safe procedure. It is therefore preferred in older and 
compromised patients, who need a supravesical shunt instead of ileal coduit as this 
type of urinary conversion requires a long intestinal segment to create a pouch as 
well as longer operative time. Therefore, this invasive method is limited to patients in 
good general condition with long life expectancy52,53. 
Earlier, a stomal stenosis rate of about 50% in cutaneous ureterostomy has 
limited its application restricting to patients with hydroureter54. 
Claman and his colleagues suggested that one could succeed in transplanting 
even a normal-calibre ureter to skin, as long as basic principles of preservation of 
blood supply and avoidance of angulation and tension are respected55.  
After development of many techniques and improvement of surgical 
dissections recent data in a retrospective comparison with short or median follow-up 
of 16 months showed that the diversion-related complication rate was considerably 
lower for ureterocutaneostomy compared to an ileal or colon conduit56. 
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1.6.1.2 Ileal conduit 
This is the most common form of diversion used in conjunction with 
cystectomy. A 15- to 20-cm-long distal ileal segment is isolated, and ureters are 
implanted in the proximal end. The stoma is usually below and to the right of the 
umbilicus34. 
A colonic conduit is most often used when high-dose irradiation has been 
given previously. When an ileal conduit is used in such patients, the risk of 
complications is very high34. 
Up to 48% of the patients undergoing ileal coduit develop early complications 
including urinary tract infections, pyelonephritis, uretero-ileal leakage and stenosis51.  
An increase in complications was seen with increased follow-up after a 
minimum of 5 years .the rate of complications increased from 45% at 5 years to 94% 
in those surviving longer than 15 years57.  
 
1.6.1.3 Continent cutaneous urinary diversion 
A high-pressure detubularised ileal reservoir can be used as a continent 
cutaneous urinary diversion wherein urine is emptied at intervals by clean intermittent 
self-catheterization. Gastric, ileocecal and sigma pouches have also been described. 
Ureters have to be placed in an antireflux manner58. 
Different antireflux techniques can be used, namely 1. Appendiceal 
techniques, pseudoappendiceal tubes fashioned from ileum or right colon, and the 
ileocecal valve placation 2. Tapered and/or imprecated terminal ileum and ileocecal 
valve. 3. Use of the intussuscepted nipple valve or, more recently, the flap valve, 
which avoids the need for intussusception. 4. Provision of a hydraulic valve50,59. 
The cutaneous ileocecal pouch is a safe and proven technique for continent 
urinary diversion in patients in whom orthotopic pouch urinary diversion is not 
feasible. Continence mechanisms have acceptable complication rates and offer 
highly satisfactory continence rate with daytime and night time continence 
approaching 93%60. 
Mansson and colleagues found no difference in overall quality of life in men 
undergoing continent cutaneous diversion when compared with orthotopic 
neobladder61. 
 
1.6.1.4 Ureterocolonic diversion 
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The oldest and most common form was primarily a refluxive and later an 
antirefluxive connection of ureters into the intact rectosigmoideum (uretero 
[recto]sigmoidostomy). Most of the indications for this procedure have become 
obsolete due to a high incidence of upper urinary tract infections and the long-term 
risk of developing colon cancer There is also generally a 10- to 20-year delay before 
the cancer becomes manifest. Because cancer incidence is significant in patients 
with ureterosigmoidostomies, patients should do routine colonoscopies on a 
scheduled periodic basis50,62,63. Bissada et al found that renal function remained 
stable in 92% of their patients64 . 
Bowel frequency and urge incontinence were additional side-effects of this 
type of urinary diversion. However, it may be possible to circumvent the above-
mentioned problems by interposing a segment of ileum between ureters and rectum 
or sigmoid in order to augment capacity and to avoid a direct interaction between 
urothelium, colonic mucosa, together with faeces and urine65. 
 
1.6.1.5 Orthotopic neobladder 
The first extensive clinical experience with orthotopic substitution was reported 
by Camey and Le Duc in 1979 in male bladder cancer patients66. 
An orthotopic bladder substitution to the urethra is now commonly used both in 
men and women. Contemporary reports document the safety and long-term reliability 
of this procedure. In several large centres, this has become the diversion of choice 
for most patients undergoing cystectomy34,67,68. 
The terminal ileum is the gastrointestinal segment most often used for bladder 
substitution and there is less experience with ascending colon, including caecum, 
and the sigmoid34,69. 
The emptying of the reservoir anastomosed to the urethra requires abdominal 
straining, intestinal peristalsis and sphincter relaxation. Currently, it is not possible to 
recommend a particular type of urinary diversion. However, most institutions will 
prefer ileal orthotopic neobladders and ileal conduits based on clinical experience70. 
The only oncologic contraindication to orthotopic diversion is the presence of tumor 
on the urethral margin, which can be safely checked intraoperatively51. 
 
1.6.2 The ileal orthotopic neobladder 
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1.6.2.1 Contraindications 
The absolute oncological contraindication is a positive frozen section or 
positive soft tissue margins other absolute non- oncological contraindications include 
Urinary stress incontinence, a damaged rhabdosphincter or incompetent urethra, 
Impaired renal function (serum creatinine > 150– 200 lmol/l) and severe intestinal 
diseases (e.g., Crohn’s disease, short bowel syndrome). 
Relative contraindications include tumour infiltration of the distal prostatic 
urethra in men or bladder neck in females, impaired intellectual capacity, dexterity 
and mobility9. 
 
1.6.2.2 Basic principles 
The two important properties for continent urinary reservoir construction are to 
store urine at a low pressure without significant high-pressure reflux71. 
Detubularized and folded segments provide these characteristics using shorter 
length of bowel needed compared with non detubularized segments72. Ileum is the 
preferred bowel segment because it has less contractility and better compliance 
compared with colon and cecum. 
Based on Laplace’s law, the pressure of a reservoir is defined as P = T x 2 D / 
R, in which P is pressure, T is the mural tension, D is the thickness of the wall, and R 
is the radius. Thus, intraluminal pressure is inversely correlated to the radius of a 
spherical reservoir. A tubular segment with its small radius will reach already-high 
kidney-deteriorating intraluminal pressures at low volumes. A spherical reservoir, 
however, will maintain the largest capacity with the lowest pressure due to a larger 
radius73. 
Other advantages of the spherical reservoir are a maximum volume to surface 
area ratio, with maximal volume and minimal reabsortive surface area; 
detubularization and cross-folding of the bowel segment render coordinated 
contractions impossible and minimize the development of high pressure peaks; with 
maximum radius, wall tension is also maximal and thus a sensation of filling is more 
likely74. 
As a result of mucosal atrophy over the long term, ileal segments have less 
reabsorption of urinary wastes and electrolytes compared with colonic segments75.  
 
1.6.2.3 Uretero ileal anastamoses 
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a) Surgical principles 
Although many techniques have been described to make the various types of 
ureterointestinal anastomosis, certain principles are applied to all the anastomosis 
regardless of type. 
 As much ureter as needed should be mobilized so that there should be no 
redundancy or tension on the anastomosis.  
 Mobilization should not strip the ureter of its periadventitial tissue because it is 
in this tissue that the ureter’s blood supply courses.  
 The ureter should be cleaned of its adventitial tissue only for 2 to 3 mm at its 
most distal portion where the ureter-intestinal mucosa anastomosis is to be 
performed. 
 The ureterointestinal anastomosis should be performed with fine absorbable 
sutures, which are placed so that a watertight mucosa-to-mucosa apposition is 
constructed. 
 The intestine should be brought to the ureter and not vice versa (i.e., the 
ureter should not be extensively mobilized so that it can be brought into the 
wound to the bowel lying on the anterior abdominal wall)50. 
 In a randomized study stented versus non stented anastomosis showed that 
complications were reduced and allowed for early recovery of bowel activity 76. 
 
b) Refluxing or anti reflux anastamoses 
Because studies comparing refluxing versus non refluxing urinary diversion 
have generally been limited by short follow-up, patient selection bias, retrospective 
design, or relatively small patient numbers there are still controversies regarding the 
necessity of antireflux mechanism in low-pressure orthotopic substitutes77. 
Arguments of doing reflux anastamoses are that the orthotopic bladder 
substitutes are low-pressure reservoirs, as detubularized bowel segments are 
incapable of coordinated contraction and pressure generation so reflux can not occur 
as pressure inside the reservoir is lower than that of the ureters, another factor is that 
urine in the bladder substitute is sterile. In addition, the afferent tubular segment itself 
has certain dynamic antirefluxive properties due to coordinated peristalsis74. Finally 
many antireflux methods are technically challenging and are potentially accompanied 
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by considerable complications such as ureteroenteric stricture with subsequent 
upper-tract deterioration. 
Arguments for the incorporation of an antireflux mechanism in orthotopic 
neobladders include the high percentage of bacteria in ileal reservoirs and an 
antirefluxive protection of the upper urinary tract in the native bladder69. 
Currently, there is no compelling evidence of whether a refluxing isoperistaltic ileal 
segment or a non refluxing (eg, subserosal, nipple) ureteral implantation will provide 
better long-term protection of the upper urinary tract34. 
 
c) Techniques of ureteroileal anastamoses  
 
 Refluxing techniques 
I. Bricker Anastamoses:  
 This is a refluxing end-to-side ureter–small bowel anastomosis that is simple to 
be performed and has a low complication rate78. The adventitia of the ureter is 
sutured to the serosa of the bowel. Sutures approximate the ureter to the full 
thickness of the mucosa and serosa. 
 
 
II. Wallace Technique: 
 Refluxing anastomosis in which the end of the intestine is sutured to the end of 
the ureter79. 
 Both the Bricker and the Wallace anastomosis provide acceptably low stricture 
rates. However the walllace technique shows better outcomes80. 
 
 Non Refluxing techniques 
I. Le Duc Technique: 
 The ureter implanted and introduced into the lumen of the reservoir via a 
transmural non refluxing channel and left unfixed intraluminally81. 
 
II. Split-Nipple Technique: 
 The ureter is spatulated approximately 1 cm and folded back to form a split-
cuff nipple. The corners are sewn to each other except for a small gap proximally to 
prevent constriction. The ureter is then placed into the bowel such that it protrudes 
through the mucosa82. 
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III. Kock ileal valve: 
 The Kock nipple antireflux technique uses an ileal segment as an antireflux 
mechanism to create an intussuscepted ileal valve83. The ureters then implanted 
directly in the ileal segment 
 
IV. Serous-lined extramural tunnel: 
 Placing the ureters directly into serous-lined extramural tunnels84 provides 
reflux protection in W shaped reservoirs. 
 
1.6.2.4 Techniques for ileal orthotopic substitution 
 
 Orthotopic substitution on a U-shaped and cross-folded reservoir (‘‘Goodwin 
principle’’) 
 
I. Camey II 
 A total of 65 cm of ileum is isolated. The ileum is placed in a transverse U 
orientation,the ureteroileal anastomosis is performed by a Le Duc technique85.  
 
II. Studer ileal neobladder 
 This technique uses a 60- to 65-cm segment of terminal ileum. The distal 40- 
to 45-cm segment is opened antimesenterically and serves as the reservoir, whereas 
the proximal 20- to 25-cm ileal segment remains intact and serves for ureteral 
implantation and prevention of reflux by isoperistaltic waves. The proximal end of the 
afferent intact segment is closed, and after spatulating and stenting the ureters, the 
ureterointestinal anastomosis is performed separately for both ureters with an end-to-
side technique at the proximal end86. 
 
III. The orthotopic Kock ileal pouch 
 Two approximately 22-cm distal ileal segments are placed in U-form to create 
the pouch whereas an approximately 17-cm ileal segment is used to create an 
intussuscepted 5- to 7-cm ileal valve. The ureters are then implanted directly in the 
intussuscepted ileal segment at the proximal end83. 
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IV. The T-pouch ileal neobladder 
 It has the same spherical configuration as the Kock ileal neobladder; the only 
difference is the use of an afferent ileal segment instead of an intussuscepted ileal 
valve as an antireflux system (‘‘T-limb’’)87. 
 
V. The Padovana ileal neobladder 
 A 40-cm segment of terminal ileum is used. The proximal loop is folded in a 
reverse S-shape and the ureters are implanted via two serous-lined intestinal 
troughs88. 
VI. The I pouch 
This type uses 40 cm from the terminal ileum. The ureters are joined together 
using the modified Wallace technique and then reimplanted in a subserosal tunnel at 
the upper end of the pouch89. It is called I pouch because the ureters are implanted in 
a vertical manner in the contrary to T pouch69. This type will be discussed in details 
later as it is the research topic for this thesis. 
 
 W- or M-ileal reconfiguration 
 
I. Hautmann ileal neobladder 
 W-configured spherical reservoir using approximately 70 cm of distal ileum. 
The ureters are implanted refluxively90.  
 
 
 
II. W-reservoir with serous-lined extramural tunnel 
 A 40-cm segment of terminal ileum is used. The medial limbs are sutured 
together while the two lateral flaps are joined by a seromuscular running suture to 
create the two serous-lined intestinal troughs. The ureters are anastomosized to the 
intestinal mucosa. Then the tunnel is closed over the ureters forming an antireflux 
mechanism84.  
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1.7 Objectives of the study: 
 
 
1. Evaluation of the safety of this technique and its impact on the perioperative 
outcomes especially the complication rate according to the modified clavien 
system. 
 
2. To analyze the efficacy of cystectomy and I poch ileal neobladder regarding 
the oncological outcomes including survival rates, recurrence and tumour 
stages. This will be achieved via comparing both results this technique and 
other ileal neobladder in literature. 
 
3. Assessment of the functional outcome of this new technique including the 
quality of life through various types of questionnaires and the urodynamic 
characters of the I pouch (capacity, pouch pressure, postmicturition residual 
urine and urethral closure pressure)  
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2. Materials and methods 
2.1 Study design: 
Retrospective hospital-based clinical study (oncological and functional data). 
Prospective clinical study (questionnaires and urodyamic parameters) 
 
2.2 Target population: 
All patients with bladder carcinoma that underwent radical cystectomy, both 
genders, for urothelial and non urothelial tumour at any age who attended the 
department of urology, Tuebingen University hospital, starting from January 1999 
until August 2011. 
 
2.3 Sample size: 
97 Patients 
 
2.4 Inclusion criteria: 
1. Bladder cancer patients that underwent cystectomy and I pouch neobladder 
as an orthotopic continent urinary diversion 
2. Stage T 1-4a bladder cancer 
3. any N stage 
4. M0 or M1 
5. Any tumour grade 
6. American Society of Anesthesiologists [ASA] scores 1-3. 
ASA 1: Those with no serious disease. 
ASA 2: Those who may have a serious disease, but have no limitation on their 
activities. 
ASA 3: Those with serious disease and some limitation of their activities 91. 
7. Any body mass index [BMI]. 
 
2.5 Exclusion criteria: 
1. Patients underwent cystectomy with types of diversion other that I-pouch 
neobladder. 
2. Uncontrolled coagulation disorders. 
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3. Patients with soft tissue margins. 
4. Patients with urinary stress incontinence. 
5. Impaired renal function (serum creatinine > 1.50– 2 mg/dl). 
6. Patients with severely impaired liver function. 
7. Patients with severe intestinal diseases (e.g., Crohn’s disease). 
8. Patients with impaired intellectual capacity, dexterity and mobility. 
9. Patients with life expectancy lower than 5 years. 
10. Untreated active urinary tract infection. 
11. Azotaemia. 
12. Patients who are unfit for surgery. 
13. Patients who refuse the planned procedure. 
 
2.6 Preoperative evaluation: 
1. Detailed history and physical examination. 
2. Estimation of body mass index. 
3. Routine laboratory work-up: 
 Urine analysis and urine culture 
 Renal function tests 
 Complete blood picture 
 Bleeding and coagulation profile 
 Blood sugar level 
 Liver fuction test 
 Electrolytes evaluation 
4. Imaging studies: 
a) Obligatory 
 Ultrasonography 
 Contrast computerized abdominal Tomography(CCT) or Magnetic 
Resonance Tomography (MRI) 
 Contrast computerized chest Tomography (CT) 
 Chest X ray, electrocardiography (ECG)  
b) Fakultative 
 A positron emission tomography computed tomography (PET/CT) in some 
cases with nodal invovement 
 Renal nuclear scanning when parenchymal damage is considered. 
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 Echocardiography 
5. Evaluation of the anaesthesiological risk 
According to the American Society of Anaesthesiologists (ASA) 
classification of physical status. 
6. Consent of the patient 
 
2.7 Operative Technique: 
 All patients receive a mechanical and antibacterial bowel preparation the day 
before surgery. 
 All patients are site-marked for a cutaneous stoma, instructed in the care of a 
cutaneous diversion (continent or incontinent form), and instructed in proper 
catheterization techniques if medical, technical or oncological factors preclude 
orthotopic reconstruction. 
 A vertical midline incision is made extending from the pubic symphysis 2-3 cm 
above the umbilicus (rotating around it) 
 Pelvic lymphadenectomy is done at least to the level of common iliac artery 
bifurcation depending on the stage of bladder cancer 
 Radical cystectomy is done with the trial to preserve the neurovascular bundle 
and the external urethral sphincter if oncologically feasible. 
 Good haemostasis 
 Construction of the I pouch ileal neobladder 
 
Technique of I pouch ileal neobladder construction 
 The 2 ureters are spatulated and joined together using the modified Wallace 
technique using 5-0 vicryl and stented using a Single J stent (Fig. 2). 
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Fig. (2) A. ends of the 2 ureters B. The 2 ureters spatulated C. and joined 
together according to modified Wallace technique D. The 2 ureters are stented 
with single J stents  
 
 An ileal segment 40 cm long is isolated 15-20 cm proximal to the ileocaecal 
valve and bowel continuity restored with a running suture (3-0 PDS). 
 A Goodwin pouch is formed with a U-shaped ileal plate (length of each limb: 
20 cm) that is cross-folded (Fig. 3). 
 
Fig. (3) The U-shaped ileal plate 
 
 8 cm of the paramesentric borders are sutured together to make the posterior 
wall of the future ureteric trough (Fig. 4). 
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Fig (4) preparation of the ureteric trough 
 
 Both ileal loops are opened by scissors at the antimesentric borders 2 cm from 
the beginning of the loops to the site of future ureter implantation (8 cm) to go 
medially to be paramesentric at this point and then complete the opening at 
the antimesentric border (Fig. 5). 
 
Fig. (5) Opening of the ileal loop 
 
 The ureters are sutured with the intestinal mucosa using a 5-0 running suture. 
Then the seromuscular layers of both loops are sutured together over the 
ureters thereby completing the trough (Fig.6). 
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Fig. (6) A. Placement of the 2 ureters in the though B. and anastomosized the 2 
ureters with the intestinal mucosa C. Closure of the seromuscular layer of the 
loops over the ureters completing the trough. 
 
 The upper and lower edges of the intestinal loops are joined together forming 
the configuration of the pouch according to Godwin’s principle. The single J 
stents are externalized through two separate openings in the mesentery. Then 
the edges are sutured together leaving the dependent part of the pouch to be 
connected to the urethra in males while in female all the edges of the pouch 
are closed and an opening at the most lower dependant part of the pouch is 
opened and then sutured to the urethra (Fig. 7). 
 
Fig.(7) A. upper and lower edges of the intestinal loops are joined together B. stents 
are externalized through two separate openings in the mesentery 
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2.8 Postoperative Follow up: 
 
2.8.1 Perioperative outcomes: 
  Hospital charts and physician records were reviewed to determine clinical 
outcomes 
1. Evaluation of complications according to the new modified Clavien system25.  
2. Estimation of postoperative renal function 
3. Collection of demographic characters of the patients (age, sex, number) 
 
2.8.2 Oncological outcomes: 
 The histological assessment was performed in one pathology department and 
was conducted according to the new 2009 TNM classification 
1. Reporting the oncological outcome from pathological reports including tumour 
stage, tumour type, tumour location, tumour grade, nodal stage, nodal number, 
presence of metastasis, lymphovascular invasion urethral and ureteric margins.  
2. Reporting the recurrence free survival by evaluation of the follow up CT and MR 
3. Reporting the overall survival by collecting the data from the local tumour registry. 
 
2.8.3 Functinal outcomes 
 
2.8.3.1 Questionnaire: 
Contacting living patients for sending the follow up questionnaire 
4 types of questionnaire were used 
EORTC QLQ-C30 and QLQ- BLM 
 The QLQ-C30 version 3 is a cancer-specific, self-administered, structured 
questionnaire designed for use in clinical trials92. 
  It contains 30 questions (items) measuring 3 general items Global health 
status score, functional score and symptom score. 
 For the global health score the scale ranges from 1 to 7 where 1 is very poor 
and 7 is excellent. The higher the score the better the health status. 
 For the global quality of life score the scale ranges from 1 to 7 where 1 is very 
poor and 7 is excellent. The higher the score the better the health status. 
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 The QLQ-BLM30 comprises 30 questions assessing disease symptoms, side-
effects of treatment with special consideration to urinary symptoms, incontinence and 
sexual function and some specific psychosocial issues of importance to patients with 
muscle invasive bladder cancer. 
 Items 1 to 7 address urinary symptoms and problems. The higher score the 
worse the symptoms. (Range 7-28). 
SF-36 
 The SF-36 version 1 is a multi-purpose, short-form health survey with only 36 
questions48. It yields an 8-scale profile of functional health and well-being scores as 
well as psychometrically-based physical and mental health summary measures and a 
preference-based health utility index. The 8 items are physical functioning, role of 
limitation due to physical health, role of limitation due to emotional problems, 
energy/fatigue, emotional well being, social functioning, pain and general health. 
The higher the score, the better the function (Range 0-100) 
The Gastrointestinal Quality of Life Index (GIQLI) 
 The five questions from the Gastrointestinal Quality of Life Index concerning 
bowel habits are used93 and the patients were asked to answer them retrospectively 
before doing the cystectomy (as far as they remember) and 2 weeks after the 
operation (as far as they remember) in order to determine the changes of bowel 
habits that occurred as a result from the operation. This is of special importance in 
the study to know whether the bowel habits of the patients who received an I pouch 
(with the use of only 40 cm segment of terminal ileum in contrast of most other 
neobladders) had been affected. 
 
Special type of questionnaire  
 12 questions were developed by an institutional protocol in an attempt to 
complete the items needed to be evaluated which are considered to be missed by 
the other questionnaires.  
 
2.3.8.2 Urodynamics: 
 Contacting living patients for doing the follow up urodynamics (10 patients 
accepted). 
  
28 
 After placement of a 6F transurethral dual channel catheter and a 14F rectal 
balloon catheter, the neobladder was filled at a rate of 20 mL/min with saline solution 
at room temperature. Uroflowmetry, cystometry, and urethral pressure profilometry 
were performed. The evaluated parameters were the neobladder capacity, pressure 
at maximal capacity, urine leakage, postvoid residual urine volume, and urethral 
pressure profile. 
 
2.9 Statistical analysis: 
The statistical analysis was performed using jmp 10 (2012, SAS Institute Inc., 
Cary, NC, USA).  
For univariate analysis, the Fisher’s exact/Pearson chi-square test was used 
for nominal data and the Student’s t-test for scaled data. All P-values were two-sided 
with P < 0.05 considered to indicate statistical significance. Values are given as 
mean, median and standard deviation for all continuous variables or as median 
(range) for nonparametric variables. Kaplan Meyer curves were used for the overall 
survival data and recurrence free survival data. 
 
2.10 Ethical considerations: 
 
Confidentiality: 
The confidentiality of all participants admitted to this study is protected to the 
fullest extent possible. The study participants are not identifiable by name in any 
report or publication resulting from data collected in this study. 
 
Ethical committee approval 
The ethical committee of Tübingen University approved the questionnaire 
delivered to the patients as well as the urodynamic follow up study (Ethical approval 
number 063/2012BO2). 
 
Research statement: 
Ethical aspects, whether substantial or procedural, is implicated in this study. 
Before participants were admitted in this study, the purpose and nature of the study 
as well as risks were explained to them. The participants agreed that he/she 
understood the investigational and operative nature of this study, its inherent risks 
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and benefits, other treatment alternatives, his/her rights to terminate participation in 
this study without affecting his/her rights in having proper health care in the study 
site, whom to contact with questions regarding the study and that he/she is freely 
given an informed consent to participate in this study. 
 
Informed consent: 
The signed informed consent form is a prominent part of the participant’s study 
records and is maintained in the same manner as other records. 
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3. Results 
3.1 Preoperative data 
 
3.1.1 Number of Patients 
Between January 1999 until August 2011, 331 Patients underwent cystectomy 
and urinary diversion for bladder cancer. 
Of these 331 Patients, 97 (29.3%) underwent cystectomy and I pouch ileal 
neobladder as urinary diversion. 
3.1.2 Sex 
 25 females (25.8%) and 72 Male (74.2%) (Fig.8) 
74%
26%
Males
Females
 
Fig. (8) shows the male: female percentage of the I pouch patients 
3.1.3 Age 
 Median age at the time of cystectomy was 65 (42-84) years 
 Age groups at cystectomy are as follow (Fig.9). 
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Fig. (9) shows the different age groups of the I pouch patients 
 
3.2 Pathology 
 
3.2.1 Tumour type 
 Pure urothelial bladder carcinoma was present in 91 patients, squamous cell 
carcinoma in 5 patients and only one patient had mixed components of urothelial and 
adenocarcinoma. Pure adenocarcinoma or sarcoma did not occur in this series (Fig. 
10). 
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Fig.(10) shows the different types of tumour pathology in the I pouch patients 
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3.2.2 Tumour stage 
 
pTa:  7 cases had non invasive papillary carcinoma 
pT1:  21 cases showed infiltration to the sub epithelial tissues 
pT2a: 17 cases had only superficial muscle layer invasion 
pT2b: 18 cases with deep muscle invasive bladder cancer 
pT3a: 15 cases had microscopic extravesical infltration 
pT3b: 13 cases had macroscopic extravesical infltration 
pT4a: 6 cases showed infiltration to the prostate 
pT4b: no cases with pelvic or abdominal wall infltration 
pTis:  30 cases had associated carcinoma in situ (Fig. 11). 
7
21
17 18
15
13
6
0
30
0
5
10
15
20
25
30
Number
pTa pT1 pT2a pT2b pT3a pT3b pT4a pT4b associted
CIS
Tumour stage
 
Fig. (11) shows the different tumour stages in the I pouch patients 
 
3.2.3 Tumour grade 
 The tumour grades of patients underwent cystectomy and I pouch are shown 
in (Fig. 12). 
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Fig. (12) shows the different tumour grades in the I pouch patients 
 
3.2.4 Tumour site 
 Tumour occurred in different regions of the bladder (side walls, bladder dome, 
anterior wall, trigone, bladder base, bladder-neck, posterior wall, ureteric orifices and 
perineural) (Fig.13). 
 
43
15
12
10
20
6 5
13
2
0
5
10
15
20
25
30
35
40
45
Number
side walls bl. dome bl. base ant.wall post.wall bl.neck trigone ur.orifices perineural
Tumour site
Fig. (13) shows the site of the tumor for the I pouch patients 
 
3.2.5 Tumour multifocality 
  
34 
78 patients had a single tumour and 29 patients had multifocal tumour (Fig.14). 
73%
27%
Single site Multifocal
 
Fig. 14 shows percentage of tumor multifocality in the I pouch patients 
 
3.2.6 Lymph nodes number 
 The median number of lymph nodes retrieved is 20 (0-38). 
 
3.2.7 Node stage 
 The following figure showed the various node stages for all patients (Fig. 15). 
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Fig.( 15) shows nodal stage for the I pouch patients 
 
3.2.8 Distant metastasis at time of cystectomy (M Stage) 
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 Only 3 patients had distant metastases (M1) at time of cystectomy, one patient 
had metastases in the lung, one to the peritoneum and a neuroendocrinal metastasis 
(Fig. 16). 
97%
3%
M0
M1
 
Fig.( 16) shows distant metastases at time of cystectomy for the I pouch patients 
 
3.2.9 R Stage 
91 patients had no residual tumour after cystectomy (R0) 
Only 6 patients had microscopic positive resection margins after cystectomy 
with clinical evidence of negative margin at the time of radical cystectomy. 
No patients experienced R2 (macroscopic residual tumour) (Fig. 17). 
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Fig.( 17) shows R stage for the I pouch patients 
 
3.2.10 L stage and V Stage 
The lymphovascular invasion of the removed bladders is as following 
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LX: Lymphatic vessel invasion cannot be assisted in one patient 
L0: No lymphatic vessel invasion in 69 patients 
L1: Lymphatic vessel invasion in 27 patients 
Vx: Venous invasion cannot be assessed in 2 patients 
V0: No venous invasion in 87 patients 
V1: Microscopic venous invasion in 8 patients 
 
3.2.11 Urethral and ureteral margins 
 Only 4 patients had positive urethral margins (4.1%) in the final specimen 
(formalin-fixed, parafferine embedded), 3 of them were positive in frozen section. All 
of them are CIS. 
 Ureteral margins showed positive results in frozen sections in 5 patients (2 
right ureter and 3 left ureter). 8 patients showed positive results in the final specimen 
(formalin-fixed, parafferine embedded) (3 right ureter and 5 left ureter) all of them are 
CIS. 
 
3.3 Survival: 
3.3.1 Recurrence free survival  
 Fig. 18 shows Kaplan Meyer curve for recurrence free survival. The mean time 
of follow up was 35 months. (Median 23.9 months, range 1.9-107.2) 
 
Fig. (18) shows recurrence free survival in the 97 patients with I pouch neobladder 
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Number of patients with recurrences at given intervals (Table 4). 
 
Time (in months) 0 12 24 36 48 60 
Number of patients 
died 
0 18 24 29 31 33 
Survival rate 100 % 79.8 % 71.4 % 63.2 % 59.2 % 55.1 % 
 
Table (4) shows number of I pouch patients with recurrences at given intervals 
  
Recurrence free survival for patients according to tumour and lymph node stage 
 The 5 years recurrence free survival for patients with organ confined tumour 
and negative lymph nodes (≤pT2b, N0) was 70.8 % (Fig. 19). 
 
Fig. (19) shows recurrence free survival in patients with (≤pT2b, N0) (N=58) 
 
 The 5 years recurrence free survival for patients having non organ confined 
tumour and positive lymph nodes (>pT3a and pN1 or pN2) was 11.7 % (Fig.20) 
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Fig. (20) shows recurrence free survival in patients with (>pT3a and pN1 or pN2) 
(N=20) 
 
3.3.2 Cancer specific survival 
 Fig 21 shows Kaplan Meyer curve for cancer specific survival. The median 
time of follow up was 40.6 months, (range 3.3-107.2) 
 
Fig. (21) shows cancer specific survival in the 97 patients with I pouch neobladder 
 
  
39 
Number of patients died due to urothelial cancer at given intervals (table 5) 
 
Time (in months) 0 12 24 36 48 60 
Number of patients 
died due to cancer 
0 8 18 22 23 25 
Survival rate 100 % 91.4% 79.7 % 74.3 % 72.8 % 67.9 % 
 
Table (5) shows number of patients died due to cancer recurrences at given intervals 
 
3.3.3 Overall survival 
 Fig 22 shows Kaplan Meyer curve for overall survival 
 Median time of follow up was 40.6 months, (range 3.3-107.2) 
 
Fig. (22) shows overall survival in the 97 patients with I pouch neobladder 
 
Number of patients died at given intervals (table 6). 
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Time (in months) 0 12 24 36 48 60 
Number of patients 
died 
0 8 18 22 25 28 
Survival rate 100 % 91.4% 79.7 % 74.3 % 69.2 % 62.2 % 
 
Table (6) shows number of patients died at given intervals 
 
Over all survival for patients according to tumour stage and lymph node stage 
The 5 years overall survival for patients having organ confined tumour and negative 
lymph nodes was only 76.4 % (Fig.23) 
 
Fig. (23) shows overall survival in patients with (≤pT2b, N0) (N=58) 
 
 The 5 years overall survival for patients having non organ confined tumour and 
positive lymph nodes (>pT3a and pN1 or pN2) was 11.5 % (Fig. 24).  
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Fig. (24) shows overall survival in patients with (>pT3a and pN1 or pN2) (N=21) 
 
3.4 Complications: 
 Thirty-five (36.1%) patients had complications in the early postoperative period 
(30 days after operation), with addional 3 patients experienced complications in the 
late postoperative period (90 days after the operation) making the total complication 
rate 39.2%. 
 One complication occurred intra operatively and treated during the operation 
(intestinal injury → repair) which can not be accurately calculated by the modified 
Clavien grading. A patient experienced a non surgery related cerebral aneurism 
which was treated medically. 
 The other 37 complications (table 7) are grade I (10 patients), grade 2 (11 
patients) grade IIIA (3 Patients) grade IIIB (9 Patients) IVA (2 Patients).grade IVB 
(one Patient) and grade V in 2 patients (Fig.25). 
 The cause of death was pulmonary embolism in one patient and intestinal 
leakage and subsequent peritonitis in the other. 
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 Fig. (25) Number of complications graded according to the modified Clavien system26 
 
  
Type of complication Number of 
patients 
Early Late Grade 
Fever > 38.5 4 4 0 I 
Hypokaleamia 3 3 0 I 
Delayed intestinal mobility 2 2 0 I 
Prolonged vomiting 1 1 0 I 
Blood transfusion 4 4 0 II 
Paralytic ileus 3 3 0 II 
Lynphocele → conservative tive 
treatment 
2 2 0 II 
Scrotal swelling 1 1 0 II 
Wound infection 1 1 0 II 
Lymphocele → percutaneous      
drainage 
3 2 1 IIIA 
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Obstruction → treated 
endoscopicaly by antegrade JJ 
4 3 1 IIIB 
Intestinal obstruction → 
 Resection - reanastamosis 
2 2 0 IIIB 
Rectal injury → repair 1 1 0 IIIB 
Burst abdomen→ Closure 1 1 0 IIIB 
umbalical hernia → Repair 1 0 1 IIIB 
Hemiparesis 1 1 0 IVA 
Lung emboli 1 1 0 IVA 
Septic schock 1 1 0 IVB 
Death 2 2 0 V 
Total 38 35 3  
Table (7) shows different type of complications occurred in the postoperative 
period in patients with I pouch 
 
3.5 Postoperative functional data: 
3.5.1 Spontaneous voiding  
 93 patients of 95 patients can micturate spontaneously (97.9%) with only 2 
patients requiring CIC (clean intermittent catheterization) to empty their neobladders. 
 
3.5.2 Residual urine after micturition 
 The median volume of postmicturition residual urine was 0, (range: 0-200).  
 
3.5.3 Postoperative reflux 
 Only one patient had direct postoperative reflux (1%) detected by 
postoperative voiding cystogram. 
 
3.5.4 Postoperative hydronephrosis 
 16 patients developed some degree of hydronephrosis in the early 
postoperative period (16.5%). In 9 of those patients the hydronephrosis required no 
treatment and resolved spontaneously (9.3%). 
 The remaining 7 patients required intervention to treat the hydronephrosis. 
Four patients required temporary PCN and JJ, one patient had temporary JJ stent 
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only and only 2 patients had to undergo surgical intervention. Thus, the true 
ureterointestinal stenosis rate in the 97 patients was collectively 2.1 % (Fig.26). 
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Fig. (26) shows ureterointestinal obstruction occurred in patients with I pouch and its 
management 
 
3.5.6 Neobladder capacity 
 The mean capacity of I pouch neobladder was 235 ± 109.2 ml, (range:50-550). 
 
3.5.7 Urinary tract infection 
 The median number of UTI per year was 0, (range: 0-2). 
 
3.6 Questionnaire results: 
 63 patients were contacted. From those only 48 patients were reached and 
informed about the study and asked to answer the questionnaire. Thirty nine patients 
only accepted to participate. 
 The questionnaire were printed in German language and sent with mail to the 
39 patients. Thirty three (52.4%) patients sent the full answered questionnaire back 
to our hospital. 
The median follow up time from cystectomy date to the date of answering 
questionnaire was 44 month (range 9-89) 
 
3.6.1 QLQ-C30 
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 It consists of 30 questions that measure three big items (Global health status / 
QoL, Functional scales and symptoms scales). 
 
3.6.1.1 Global health status  
 It has a separate question (No 29) in which the patient estimates on a scale 
his overall health status. The scale ranges from 1 to 7 where 1 is very poor and 7 is 
excellent. The higher the score the better health status. 
 The mean score was 75.2 ± 20.5, (Median score was 83.3; range: 16.7-100). 
 
3.6.1.2 Quality of life 
 It has a separate question (No 30) in which the patient estimates on a scale 
his overall quality of life. The scale ranges from 1 to 7 where 1 is very poor and 7 is 
excellent. The higher the score the better quality of life. 
 The mean score was 73.2 ± 19.5, (Median score was 83.3; range 33.3-100). 
 
3.6.2 QLQ-BLM30  
 It consists of 30 question evaluating different items. 6 questions (from 8 to13) 
were excluded from analysis because they are assessing urostomy problems and 
another one because it is applied only if the patient uses a catheter. 
 
3.6.2.1 Urinary symptoms 
 These are 7 items describing the urinary symptoms, Each item ranges from 1 
to 4 in which 1 indicates that the patient does not have any symptom and 4 indicates 
that the patient suffers from the symptom very much. 
 The urinary symptom score ranges from 0 to 100. The higher the score the 
worse the condition. 
 The mean score was 32.2 ± 20.2, (Median score was 28.6; range 0-85.7) 
 
3.6.2.2 Sexual function 
 These are 8 questions for reporting sexual function and sexual problems 
occurring during sexual activity. Men have different questions from women. The 
EORTC group advised that every item should be analyzed separately. As a reason 
that some of the questions are not fully answered from many patients we will analyze 
only whether or not the patients are sexually active. 
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 Twenty one patients (63.7%) remained sexually active after the operation 
while only 12 (36.3%) patients lost their sexual activity (Fig. 27). 
18
3
8
4
0
5
10
15
20
Number
sexually active sexually inactive
Males Females
 
 
Fig (27) shows postoperative sexual function for both males and females 
 
3.6.2.3 Other BLM-30 items 
These are 8 items evaluating different parameters (future perspective, 
abdominal bloating and flatulence and body image). Scoring ranges from 8-32. The 
higher the score the worse the symptoms. 
The mean score was 15 ± 4.3, (median 15; range 8-23) 
 
3.6.3 SF- 36 
Table(8) lists the different parameters of Sf-36 for the I pouch patients 
 The higher the score the better the quality of life regarding the evaluated item. 
 
SF-36 Item Mean SD Median Range 
SF-36 Physical functioning 78.2 25.7 85 10-100 
SF-36 Role of limitation due to 
physical health 
76.5 37.5 100 0-100 
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SF-36 Role of limitation due to 
emotional problems 
80.8 37.3 100 0-100 
SF-36 Energy/Fatigue 73.9 20.9 80 15-100 
SF-36 Emotional well being 76.5 19.9 84 28-96 
SF-36 Social functioning 80.8 21.7 87.5 25-100 
SF-36 Pain 88.9 18.3 100 32.5-100 
SF-36 General health 65.6 21.8 70 30-100 
Table (8) shows the Sf-36 different parameters for the I pouch patients 
 
3.6.4 The Gastrointestinal Quality of Life Index (GIQLI) 
 These 5 items concerning bowel habits were answered from the patients and 
the score of change in bowel habits was calculated. The mean change was 1.6 ± 2.6 
and median change was 0 range (-1-10) 
 
3.6.5 Special questionnaire (Tübingen questionnaire) 
 Use of vitamin B12 
 One patient use vitamin B12 supplements (3%) and 32 patients did not require 
(97%). 
 Use of Sodium bicarbonate 
13 patients use NAHCO3 (39.4%), while 20 patients do not (60.6%). 
 Straining by micturition 
 22 patients need to strain during micturition (66.7%), while 11 do not (33.3%). 
 Urinary tract infection 
 Only 14 patients experienced postoperative UTI (42.4%). Median number of 
UTI per year is 0 (0-5). From those 14 patients only 4 experienced ever fever with 
UTI (12.1%). 
 Volume of urine  
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 The patients were asked to roughly estimate the amount of voided urine by 
each micturition. 
 The mean volume was 301.5 ± 91.4, (median 250, range 150-550). 
 Number of pads used 
 Mean number of pads used during day time is 1.1 ± 1.3. (Median 1, range 0-
5). 
 Mean number of pads used at night time is 1.1 ± 0.8. (Median 1, range 0-4) 
(Fig. 28). 
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  Fig (28) shows number of pad used by the patents day and night 
 
3.7 Urodynamic results: 
 To verify the results of our questionnaire analysis, patients were asked to 
undergo urodynamics work-up. 
 Ten patients accepted to do a complete follow up urodynamics in our 
department. 
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3.7.1 Cystometric capacity 
 The mean cystometric capacity was 445 ± 88 ml, (median 460 ml; range 300-
590) (Fig.29). 
 
Fig. (29) shows box plot of cystometric capacity. Box represents the range between 
25 and 75% percentile of the values and horizontal line represents the mean 
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3.7.2 Neobladder filling pressure 
 The mean neobladder pressure at maximum filling was 19 ± 7.9 cmH2O, 
(median 18 cm H2O; range 5-29) (Fig.30). 
 
Fig. (30) shows box plot of neobladder pressure at maximum filling. Box represents 
the range between 25 and 75% percentile of the values and horizontal line 
represents the mean 
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3.7.3 Urethral closing pressure 
 The mean urethral closing pressure was 60.3 ± 36.5 cmH2O and median 55 
cmH20 (range 13-142) (Fig. 31). 
 
Fig. (31) shows box plot of urethral closing pressure. Box represents the range 
between 25 and 75% percentile of the values and horizontal line represents the 
mean 
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3.7.4 Postmicturition residual urine 
 The mean volume of postmicturition residual urine was 27.9 ± 53.3 ml and 
median 15 ml (range 0-170) (Fig. 32). 
 
Fig. (32) shows box plot of postmicturition residual urine. Box represents the range 
between 25 and 75% percentile of the values and horizontal line represents the 
mean 
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3.7.5 Vesical pressure during micturition 
The mean vesical pressure during micturition was 73.9 ± 25.8 cmH2O and median 73 
cm H2O (range 35 -117) (Fig. 33) 
 
Fig. (33) shows box plot of vesical pressure during micturition. Box represents the 
range between 25 and 75% percentile of the values and horizontal line represents 
the mean 
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4. Discussion: 
 In this chapter we will discuss the results of the I pouch neobladder as 
technique of urinary diversion with the results of other ileal neobladders in literature 
in an attempt to evaluate the outcomes of this new technique regarding oncological 
and functional aspects. 
 
4.1 Survival 
The choice of urinary diversion should not have a major impact on survival, as 
nerve sparing is only attempted if reasonable from an oncological stand point74.  
Outcome is best characterized by disease-specific survival versus overall 
survival, which underestimates the impact of treatment in patients with favourable 
tumour and nodal stage. According to a multi-institutional database of 888 
consecutive patients undergoing cystectomy and lymphadenectomy for bladder 
cancer, mean recurrence-free survival at 5 years was 58% and 66% for bladder 
cancer-specific survival42. 
 The recurrence-free and overall survival in a large single centre study of 1,054 
male and female patients was 68% and 66% at 5 years, respectively29. 
In our series the 5 years recurrence free survival, cancer specific and over all 
survival was 55.1%, 67.9% and 62.2% respectively which are comparable to other 
series results. In the previous large single centre study it was shown that the 5-yr 
RFS for patients with organ-confined, lymph node–negative tumours was 85%, and 
OS was 78%.  
The 5-yr RFS and OS for patients with non–organ-confined, lymph node– 
negative tumours was 58% and 47% respectively29. We found that the 5-yr RFS for 
our patients having organ-confined, lymph node–negative tumours was 70.8 % and 
the 5-yr OS was 76.4 %. The results of our study are in the same range of other 
studies either single or multi centre studies regarding the survival. Recent studies 
showed that recurrence-free survival rates at 2 and 3 years correlate with and are 
potential intermediate surrogates for 5-year overall survival in patients treated with 
radical cystectomy for muscle invasive bladder cancer regardless of adjuvant 
chemotherapy. 
The overall agreement between 2-year disease-free survival and 5-year 
overall survival was 79%, and between 3-year disease-free survival and 5-year 
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overall survival 81 %94. These data were recently externally validated with about 
2,500 patients confirming that disease-free survival rates at 2 and 3 years are valid 
surrogate markers for survival outcome after radical cystectomy95. In this study the 2 
and 3 years recurrence free survival were 71.4% and 63.2%, respectively, while the 5 
years overall survival was 62.2%. 
 
4.2 Complications 
 Two big issues appear when we discuss the complications of cystectomy and 
urinary diversion. One is that there is a real lack of standardised reporting of 
complications after RC; thus, it is almost impossible to compare different series of RC 
cases. The other is that it may sometimes be difficult to separate the complications 
arises from each procedure alone27. 
 
4.2.1 Mortality 
 There is considerable variability in the mortality rates reported in the urologic 
literature, with figures ranging from 0.8%21 to 8.3%96.Various technical improvements 
in the surgical and anesthesia techniques, multi disciplinary approach for correction 
and control of comorbidities and early postoperative rehabilitation have produced 
salutary effect in reducing the mortality24. In our series of 97 patients only 2 (2.1%) 
patients died in the early postoperative period. The cause of the relatively low 
mortality rate can be explained by that operations were done in a high center volume 
by well experienced surgeons. Both factors are known to have great impact on 
mortality97. 
 
4.2.2 Morbidity 
In an analysis of population-based data, Konety et al. reported at least one 
complication other than death occurring in 28.4% of patients98. However, the 
observed rate in studies using standardized reporting system is more than double 
that, reaching between 58% and 64%22,99. The total complication rate in our series 
was 36.1% in the early postoperative period (< 30 days) while it increased to 39.2% 
in the late postoperative period (< 90 days). Comparison between series of 
cystectomy with different types of diversion must be viewed cautiously as the patient 
characteristics differ. However, some series suggest that there are no major 
differences with regard to early complications between these groups63. 
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In a recent study comparing 4 different types of diversions after cystectomy 
((1) ileal conduit,(2) Indiana pouch (IP; (3) orthotopic diversions after 
cystectomy/neobladder, (4) orthotopic neobladders with sexuality-preserving 
cystectomy), the authors found that 44% of the patients developed early 
complications (within first 30 days). The complication rate was 48% in Ileal coduit, 
43% in Indiana pouch, 42% in neobladder, and 38% in orthotopic neobladders with 
sexuality-preserving cystectomy. Late complication rate was 51%. The complication 
rates in the ileal conduit group, Indiana pouch group, orthotopic diversions after 
cystectomy/neobladder group and orthotopic neobladders with sexuality-preserving 
cystectomy were 39%, 63%, 59%, and 60% respectively51. 
In order to find a standard way of grading surgical complications the Clavien 
system seems to be a good solution. The Clavien system for classifying surgical 
complications was originally described for patients undergoing hepatobiliary surgery 
and has subsequently been validated in a general surgery population. It is a 
straightforward and validated instrument that has already been successfully adopted 
by several urological centers22,99. The Clavien system focuses on the therapeutic 
consequences of a complication, emphasizing the level of intervention required to 
deal with it26. 
Donat et al applied a modiﬁed version of the Clavien  system utilized at 
Memorial Sloan-Kettering Cancer Center to their series of 1142 patients  undergoing 
RC and urinary diversion. 64% of patients had ≥1 complications. Of these 83% were 
Clavien grade II–V100. 
 The main limitation of the Clavien system is that it is less suitable for the 
reporting of long-term complications28. Moreover there might be some subjectivity in 
how an individual surgeon records complications. Contradictory, the obvious 
strengths of this system are that it is standardized and has been validated23.  
 Most authors now recommend that all complications from urology procedures 
should be classified according to the modified Clavien system23. 
In our series complications grades were as follow grade I (10.3%), grade II 
(11.3%) grade IIIA (3.1%) grade IIIB (9.3%), IVA (2.1%), IVB (1%) and V (2.1%). 
By considering grade I and II as minor complications 22.6% of our patients had minor 
complications while 17.6% had major complications. In the largest series of 
neobladders up to date using the Clavien grading with more than 1000 cases 36% of 
the patients had minor (grade 1 to 2) and 22% had major (grade 3 to 5) 
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complications99. Therefore these results of the I pouch are comparable to other 
series. 
 
4.2.3 Blood loss and transfusions 
The mean loss ranges from 600–1700 cm3 and blood transfusion rates are 
about 1–9%101. Acute blood loss is common at RC, and predicting blood loss and 
transfusion requirements remains difficult102. In RC, most blood loss occurs when 
dealing with the bladder vasculature and pedicles101. Meticulous intraoperative 
haemostasis and refinement in surgical techniques is important in order to decrease 
blood loss103. It has been proposed that new technical equipments such as the 
bipolar device and the harmonic scalpel can be useful104. Technical improvement of 
other fields (i.e., a better technique for dorsal venous plexus ligation) during radical 
prostatectomy may be associated with decreased transfusion rates seen over time in 
some cystectomy series21. Moreover patient selection and combined epidural and 
general anaesthesia may continue to lower transfusion rates reported in recent 
series105. 
In a recent review, LRC or robot-assisted LRC has been shown to reduce the 
operative blood loss significantly and also the operative time106. 
In our series the transfusion rate was 4.1 %. The following measure are used, 
controlled hypotensive anaesthesia, various haemostatic surgery devices such as 
bipolar devices, harmonic scalpel, stapler, oxidised cellulose, absorbable gelatine 
sponge on raw surfaces, adhesive/biologic tissue glue to minimize blood loss as was 
recommended by Lawrentschuk and colleagues101. 
 
4.2.4 Deep vein thrombosis and pulmonary embolism 
The rate of deep vein thrombosis ranges from (0.6–5.3%) and pulmonary 
embolism ranges from (0.7–6%)101. 
Risk factors for deep vein thrombosis (DVT) include age >40 yr, obesity, 
malignancy, recent surgery, prior history of pulmonary embolism (PE) or DVT, and 
pelvic lymphocoeles and haematomas107. 
In our series, DVT did not occur while pulmonary embolism rate occurred in 
one patient 1%. We routinely use low-molecular-weight heparin (LMWH) , advice our 
patients for early mobilisation and use of compression stockings as recommended101. 
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4.2.5 Paralytic ileus 
The rate of paralytic ileus ranges from (2.5–22.7%). There is no accepted or 
standard definition for paralytic ileus but is commonly used to describe temporarily 
cessation of intestinal motility101. Paralytic ileus is commonly observed within 3–5 d 
after major abdominal surgery. Factors affecting ileus occurrence are type of 
preoperative bowel preparation, fasting before surgery, intraoperative pain control, 
hypovolaemia, postoperative pain control, long-term NGT, administration of large 
amounts of saline and postoperative fasting until recovery of bowel function108. 
Recommendations for prevention are followed like minimization of surgical trauma to 
the bowel as possible, reduction of analgesic requirements, where possible, 
beginning of oral fluids on day 1and oral feeding as soon as possible 101.The routine 
use of nasogastric tube (NGT) is not required following RC, as the time of NGT 
removal does not affect ileus resolution109. 
Paralytic ileus was defined as transient functional impairment of intestinal 
motility occurring after surgery. It occurred in 3.1% of our patients.  
 
4.2.6 Wound dehiscence 
The rate of Wound dehiscence ranges from (0.5–9%)101. A recent meta-
analysis suggests interrupted closures with non absorbable sutures to significantly 
reduce wound dehiscence110. In our series wound dehiscence occurred in one 
patient (1%). Surgeon factors are important, since attention to opposing fascia and 
correct tension on the suture are of outmost importance, although it is unclear if 
preemptive tension sutures assist111. Significant factors contributing to dehiscence 
include suture-to-wound length ratio > 4112, age > 65 yr, wound infection, pulmonary 
disease, haemodynamic instability, and ostomies in the incision113. Treatment 
recommended for dehiscence involves treatment of sepsis and early repair. Unless 
the defect is too large, interrupted sutures are preferred over mesh, which should be 
avoided if any infection is present114. 
 
4.2.7 Lymphocoele  
The rate of lymphocoele ranges from (0.5–3.5%)101. In recent years, the extent 
of lymphadenectomy has increased but without associated rise in morbidity as 
claimed by specialized centres115, but there are no prospective studies of the 
incidence of lymphocele after RC with limited versus extended lymphadenectomy116. 
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For decreasing the incidence of lymphoceles, a meticulous surgical technique that 
includes proper identification and ligation or clipping of lymphatic vessels is required, 
adequate peritoneal opening for drainage of lymphatic101. Decreased lymphorrhoea 
has also been observed after subcutaneous heparin was administered in the upper 
arm instead of in the lower half of the body after lymphadenectomy117.  
Lymphocele occurred in 5 patients of our series. Two of them resolved 
spontaneously while 3 (3.1%) required intervention in the form of percutaneous 
drainage. 
 
4.2.8 Retention 
There is no clear definition for retention but in neobladders, many authors 
suggest to define retention if residual urine is between 100 ml and 200 ml depending 
on the type and size of the reservoir101. Urinary retention is much more common in 
women than in men after orthotopic reconstruction. Retention might occur early, but 
often presents after years of satisfactory neobladder function and emptying118. 
Urethral stricture must be ruled out as a cause of incomplete voiding. The 
reason for the higher rate of voiding dysfunction in women remains largely unclear. 
Most investigators assume formation of a ‘‘pouchocele’’ to be the main factor in 
retention. In their concept, lack of posterior support of the neobladder leads to 
angulation and obstruction of the neobladder-urethral junction119. Studer has 
proposed that location of the urethral opening in the pouch is an important variable86. 
Chronic retention in orthotopic bladder substitutes may be related to the initial 
capacity and configuration of the orthotopic bladder substitute pouch at the time of 
surgery. 
In general, causes include angulation of the urethra, elongation of the 
neobladder neck, position of neobladder neck—not at the lowest portion of pouch, 
lack of funnelling of neobladder neck during abdominal straining, preserved but 
dysfunctional native bladder neck, denervated proximal urethra, inadequate pelvic 
floor relaxation during voiding, neobladder hypercapacity (floppy bag) or ineffective 
Valsalva straining23. 
It is important to educate and the patient to void the bladder regularly, avoid 
excessive mucous formation and angulation just proximal to the urethral 
anastomosis. Successful conservative management may require attempts to reduce 
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mucous accumulation (e.g., N-acetyl-L-cysteine), prevention of infection, and/or 
intermittent self-catheterisation101. 
Recent experiences suggest that reducing reservoir capacity by using 
approximately 40 cm length of bowel rather than 60 cm may contribute to improved 
voiding function119. This was the fact in our series. All our patients did not experience 
retention in the 90 days postoperative period and only 2 (2.1%) required CIC after the 
long term follow up. The rate of CIC in other pouches was 7% for Studer86, 2 %  for 
Mansoura84 and 5.6% for the Hautmann poch 90. In a recent long term follow up study 
for the Hautmann pouch female patients, the rate of CIC was 58 %120. This very high 
percentage of CIC shows the big advantage of the I pouch in which CIC was not 
required by any female patient. 
 
4.2.9 Rupture (perforation) 
Generally, pouch perforation is rare in continent diversion, especially in 
orthotopic substitutes because outlet resistance is usually low. Rupture can occur 
spontaneous or during catheterization. The risk may be increased in patients who 
have had previous abdominal radiation therapy50. 
Rupture can occur due to acute (catheter trauma, mucus retention) or chronic 
over distention of the neobladder121. To decrease risk of rupture due to chronic 
overdistention, one should emphasize to the patient not to retain urine for long 
periods and void regularly every 3–4 h, and to remove residual urine at regular 
intervals36. It is a potentially life-threatening complication when it occurs; there are at 
least two deaths reported in the literature due to pouch perforation of an orthotopic 
diversion that was unrecognized50. This complication did not occur in our series. 
 
4.2.10 Chronic bacteriuria 
A positive urine culture is a common finding in patients with urinary diversion 
(UD), but this does not indicate a symptomatic infection122 . The incorporation of 
intestinal segments in the urinary tract helps bacterial growth of the skin flora, 
anaerobic bacteria, and uropathogenic strains. The bacterial strains growing in the 
reservoir change spontaneously, indicating colonization rather than infection119. As 
the intestinal neobladders lack the native immunologic defences of the normal 
bladder mucosa and prostatic secretions, bacterial colonization may progress to 
invasive tissue level infection more easily in urinary diversion34. 
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Risk factors associated with increase bacterial burden are clean intermittent 
catheterization and residual urine119. Recommendations for prevention are to exclude 
obstruction, avoid residual urine in neobladder and to ensure adequate and constant 
diuresis101. Prophylactic antibiotics are not routinely recommended to reduce risk of 
drug-resistant bacteria and drug-related adverse effects36.  
The median number of UTI per year in our series was 0, (range 0-2). In the 
long term follow up only 4 patients out of 33 (12.1 %) experienced symptomatic UTI. 
 
4.2.11 Metabolic complications 
The rate of stones in neobladders ranges in the literature from (3.9–9%)101. 
They can occur for many reasons: malabsorption may result in oxalate nephropathy; 
reabsorption of urine solutes from the reservoir, include acidosis resulting in chronic 
infections with urease-producing bacteria due to urine alkalosis123. In intestinal 
reservoirs, alterations in bowel mucosa, foreign bodies such as staples or non 
absorbable suture may also serve as a nidus for stone formation. Finally, alterations 
in intestinal mucus, particularly in the presence of infection or obstruction, may serve 
as a nidus or more importantly may interfere with emptying and thereby exacerbate 
infection and stone formation124. 
Prevention can be aided by preserving the most distal 10– 25 cm of ileum 
and—postoperatively125, by ensuring adequate reservoir size, ensure hydration and 
emptying of the reservoir reduce the risk of bacteriuria (In this respect angulation of 
conduit should be avoided and encouraged frequent voiding to ensure minimal 
residual volumes)101. Patients should be encouraged to ensure hydration and 
frequently void their neobladder to minimize residual volumes, risk of UTI and 
bacteruria. However, treatment of UTI and bacteriuria if the urine is sterile is 
controversial since about 40% of patients with an orthotopic bladder will have 
persistent bacteriuria and may have other adverse affects, such as resistant 
organisms125. 
No single case in our series experienced stones at any time of follow up. 
Various electrolyte disturbances can occur based on which segment of the gastro-
intestinal tract is chosen for urinary reconstruction: stomach, jejunum, ileum, or 
colon126. The electrolyte abnormality that occurs with the ileum and colon is 
hyperchloremic metabolic acidosis51. 
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The mechanism of hyperchloremic metabolic acidosis is due to the ionized 
transport of ammonium. Ammonium substitutes for sodium in the Na+-H+ antiport. 
The exchange of the weak acid NH4 for a proton is coupled with the exchange of 
bicarbonate for chloride. Thus ammonium chloride is absorbed across the lumen into 
the blood in exchange for carbonic acid (i.e., CO2 and water). Ammonium also gain 
entry to the blood from bowel lumen through potassium channels127. 
Hyperchloremic acidosis is most prevalent following ureterosigmoidostomy. 
Chloride absorption and bicarbonate excretion are more pronounced in the colon. 
Therefore, it is preferable to use ileum rather than colon for bladder reconstruction to 
reduce the risk of hyperchloremic acidosis, specially in the presence of renal 
impairment23. Whichever segment of bowel is used, regular voiding and drainage to 
completion are important to diminish electrolyte imbalances75. This also did not occur 
in our series. The potassium depletion is due to renal potassium wasting as a 
consequence of renal damage, osmotic diuresis, and gut loss through intestinal 
secretion. Patients with ureterocolonic diversions are more expected to have 
hypokaleamia than those with ileal diversions128. We observed only a rate of 3.1 % in 
our patients. 
Malabsorptive vitamin B12 deficiency may be a concern and a relatively 
uncommon problem129. Distal terminal ileum preservation is essential, and it may 
take 3–4 yr to deplete hepatic vitamin B12 stores. Chronic vitamin B12 deficiency is 
insidious and may result in irreversible neurologic and hematologic sequelae34. 
In the long term follow up questionnaire of our 33 patients only one patient (3 
%) reported to require vitamin B 12 supplements. 
 
4.3 Upper tract obstruction: 
Obstruction may be benign or malignant (a second primary site or a 
recurrence at the ureterointestinal anastomosis). Malignant recurrences at the 
ureteroileal anastamoses are considered to be late oncological events after radical 
cystectomy occurring after a median follow up time of 36 months9. Benign strictures 
commonly occur during postoperative year 1 and are usually asymptomatic because 
they develop slowly101. The type of ureteroileal anastomosis (Bricker vs Wallace) 
does not affect the stricture incidence80. 
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The primary cause of uretero-intestinal stenosis is ischemia. When dissecting 
the ureters at the time of radical cystectomy, it is important to avoid devascularization 
of the distal ureteric segment which is to be reimplanted119.  
Meticulous handling and preparation of the distal ureter are essential to 
minimising the risk of urine leak and postoperative stricture. Moreover ensuring good 
vascular supply, limiting the dissection, adequate calibre ureteroenteric water tight 
anastomosis, complete excision of pathologic lesions, good drainage, and a wide 
spatulated and tension-free anastomosis of mucosa to mucosa remain of paramount 
importance 69. It is also important not to angulate the ureter during reconstruction as 
that can also lead to postoperative obstruction119. 
Early diagnosis and prompt drainage (usually with a nephrostomy) are 
required to prevent consequent renal parenchymal loss and infectious 
complications130. Although endoscopic and percutaneous management procedures 
are established treatment options, open surgical revision may need to be the long-
term definitive treatment, particularly if the stricture occurs after 6 months51. The rate 
of Upper tract obstruction differs in different types of orthotopic diversions mainly due 
to the type of ureteric implantation in the newly formed neobladder. It can be 
understandable that a refluxing implantation has a less chance to be obstructed than 
implantations which include an antireflux technique. In a randomised trial tunnelling 
techniques for antireflux mechanisms carried a higher risk of stenosis131. The rate of 
ureteroileal stenosis for different types of neobladder was 2.7 % for Studer 
neobladder, 9.3% for Hautmann neobladder, 3.8 % for the serous lined extramural 
tunnel (El mansoura pouch) and 10 % for the T pouch ileal neobladder84,86,90,132. One 
of the major problems in comparing the results of different techniques of neobladders 
regarding obstruction is that there is no standard definition for it. In our series we 
differentiated between 3 types of clinical obstruction and hence different percentage 
according to each type. Sixteen and half (16.5 %) of all our patients had obstruction 
at any time during the follow up. 
This percentage decreased to 7.2 % after exclusion of the patients that 
required no treatment (they experienced hydronephrosis at a certain point that was 
self limited and spontaneously resolved). The percentage was 2.1 % after excluding 
the patients that required only PCN tube or JJ stent as a temporary treatment for 
hydronephrosis and include only the patients that required a definitive surgical 
treatment in term of open reimplantation or endourological uretrotomies. Thus with a 
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2.1 % of true obstruction our antireflux technique of ureteral implantation in a 
subserosal tunnel after anastamosing both ureters together with the modified Wallce 
technique seems to be comparable with other techniques of neobladders. 
Anastamoses of the ureter to the posterior wall of the neobladder also gives an 
advantage of placing the ureters in an easily accessible place for a possible later on 
endoscopy of the upper tract. The main advantage of the antireflux technique is to 
protect the upper tract from deterioration by preventing reflux. In our series only 1 
(1%) patient had postoperative reflux detected by postoperative retrograde 
cystography. These results are better than other techniques both using refluxing or 
antireflux anastamoses, The reflux rate for Hautmann was (3.3%), Mansoura (3%) 
and the T pouch 10 %84,90,132. 
Although techniques using antirefluxing mechanisms are still used for 
ureterosigmoidostomy or continent reservoirs with a catheterisable abdominal stoma 
due to higher intraluminal pressures, the evidence for its use in orthotopic bladder 
substitutes is equivocal34. Other causes of renal deterioration are chronic retention, 
infection due to inadequate catheterization, poor compliance, and high storage 
pressure in the reservoir and subsequent reflux119. Another cause of avoiding renal 
deterioration is the use of only 40 cm for the formation of an ileal reservoir as this 
decreases the surface area of the neobladder that is exposed to urinary constitutes 
and thus decreases their absorption through the bowel mucosa. 
 
4.4 Incontinence: 
Multiple factors influence continence including patient age and mental status, 
an intact and innervated urethral sphincter, urethral length, surgical technique, low-
pressure/large-capacity reservoir (>300 ml), absence of bacteriuria, and 
completeness of voiding23,36. Continence usually improves within the first 6 to 12 
months postoperatively as the compliance of the reservoir increases allowing storage 
of greater volume at lower pressure. Patients learn to void by performing a Valsalva 
maneuver in coordination with relaxation of the pelvic floor, resulting in spontaneous 
voiding to empty the pouch. Daytime continence is often achieved before night-time 
continence119. The various studies have demonstrated rates of good or excellent 
daytime continence at 85–90%, defined as totally dry or use of one pad per day after 
12 month from surgery34.  El Bahnasawy et al found rates of enuresis ranging from 
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27% to 50% for follow-up intervals more than 12 months in male patients with hemi-
Kock or Hautmann ileal neobladder133.  
Persistent severe incontinence is a difficult clinical problem. To decrease the 
risk of incontinence a more meticulous dissection around the prostatic apex with less 
damage to the external sphincter mechanism and membranous urethra is required36. 
Nerve-sparing cystectomy is significantly associated with improved continence 
rates134. Possible treatment strategies for incontinence are intermittent self-
catheterization, augmentation of the neobladder, peri-urethral collagen injection, 
placement of a urethral sling or implantation of an artificial urinary sphincter. Some 
patients may even need removal of the neobladder and cutaneous diversion. 
Pharmacotherapy is of little or no value119. 
The main obstacle of objective evaluation of continence with continent 
reservoirs is that it varies across series due to different methodology including 
subjective and objective definition of degrees of continence determined at different 
time points from surgery. It is recommended to assess continence by stratifying into 
daytime versus nocturnal incontinence36. The rate of day incontinence varies in 
different series of cystectomies according to the technique and the way of definition 
of incontinence. In a long term follow up study up to 20 years Studer and associates 
found that daytime continence improved quickly and reached a plateau 12 months 
after surgery. They noticed that this percentage remained stable for 7 years86. 
For the Studer neobladder they reported day continence rate reaching 92 % 
and nocturnal incontinence up to 79 %. Continence was defined according to the 
amount of urine loss as follow: continent = No single drop loss, loss of 5 to 10 ml 
daily, loss of less than 1 dl daily, loss of less than 2 dl daily and loss of more than 2 dl 
daily86. 
Another way of defining continence used for evaluation of the Hautmann 
neobladder with 11 years follow is as follow .They divide continence into 3 grades 
(good, satisfactory and incontinent). They included in the good group those patients 
that were either completely dry without use of pads for protection or the completely 
dry with the use of one pad reaching a rate of day time continence up to 83.7 % and 
night continence up to 66.3 %. They consider patients that use no more than one pad 
daily which gets wet as satisfactory continence which raised their results to reach 
(95.9 % and 95 %) for day and night continence respectively90. 
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For the Mansoura group, they did not define the day continence but define the 
night continence as patients that not use pads or medication and had a night time 
frequency of 2 voids or less. The continence rate was 93.3% and 80% for day and 
night, respectively84. In our series the continence rate at long term follow up for the 
group of patients that answer the questionnaire was 75.8 % and 84.9 % for day and 
night continence respectively. (Continence was defined as patients that are 
completely dry or using one pad for protection). This percentage increased to 80 and 
90 % for day and night continence after including only the patients that underwent a 
nerve sparing radical cystectomy. 
One might think that the relatively lower continence rate in our series might be 
attributed to the decreased bladder capacity due to the use of only 40 cm of ileum in 
its reconstruction. However this is not the fact as bladder capacity detected by 
urodynamic studies showed that it is comparable with the other forms of neobladders 
even those using 60 cm from the bowel. Another contributing factor is that nerve 
sparing cystectomy was not oncologically feasible in one third of the patients. By 
contrast the high night continence rate underlines that the capacity of I pouch is high 
enough to store large volume of urine at night. 
 
4.5 Quality of life: 
The published literature on quality of life (QOL) after radical cystectomy is 
rather extensive. However, the scientific quality is low. In 2005 by Porter et al135 
performed a systemic review of a total of 378 studies Based on their inclusion criteria 
(adult patients, bladder cancer, comparative studies, original research, primary study 
outcome related to QoL, use of defined QoL instruments), only 15 of these 378 
studies were appropriate for analysis. Moreover, no randomized controlled study has 
been undertaken, which would be desirable but probably difficult to conduct. Only 
one study was prospective. Only two-thirds used validated QoL instruments, and only 
73% used bladder cancer disease-specific instruments. Although two studies have 
shown a statistically significant difference in QoL in favor of neo-bladders136,137. 
Published evidence does not support an advantage of one type of reconstruction 
over the other with regard to QOL. The reason for such results may be that patients 
are subjected preoperatively to method-to patient matching and therefore they are 
prepared for disadvantages and advantages associated with different methods34. In 
our series we used many types of questionnaire in an attempt to evaluate different 
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parameters of quality of life. We use the SF-36 as a general questionnaire type. In 
our series the results of different items of SF 36 questionnaire are high ranging from 
65.5 for general health status, 88.9 for presence of body pain. 
SF-36 Physical functioning (PF) was 78.2 ,SF-36 Role of limitation due to 
physical health (RP) 76.5, SF-36 Role of limitation due to emotional problems (RE) 
80.8, SF-36 Social functioning (SF) 80.8, SF-36 Body Pain (BP) 88.9 and SF-36 
General health (GH) 65.6. A Japanese group performed the SF-36 questionnaire 
analysis for different types of orthotopic reservoirs and also for an age matched 
control group138. The results for different Items of SF-36 for the studer pouch, 
Hautmann pouch and the control group were considerably lower with rates of 47.6, 
47.6, 47.7 for PF, 46.8,   46.4, 48.8 for RP, 51.1, 51.8, 49.7 for BP, 48.9, 49.5, 49.6 
for GH, 47.9, 48.7, 49.6 for SF, 44.1, 44.3, 49.8 for RE respectively. In the view of 
these results, all the SF-36 parameters by I pouch patients was better than 
parameters of patients with Studer and Hautmann puoches done by this Japanese 
group.  
 In another group from United Kingdom136 used the SF-36 questionnaire to 
compare the quality of life between patients with ileal conduit and patients with 
orthotpic diversions the results were as follow for different parameters. Orthotopic 
neobladder SF-36 results were 77.4 for (PF), 68.5 for (RP), 86.5 for (RE), 79.2 for 
(SF), 78.3 for (BP) and 73.8 for (GH). Ileal conduit diversion SF-36 results were 61.8 
for (PF), 59.8 for (RP), 79.0 for (RE), 79.7 for (SF), 81.4 for (BP) and 68.2 for (GH). 
From these results it is obvious that the patients in our series receiving I pouch as the 
type of diversion have apparently a comparable quality of life to other forms of 
diversions and also to ileal conduit patients. 
The QLQ- C30 was used as a cancer specific questionnaire. In our series the 
score of the global health status was 75.2 ± 20.5 and the quality of life score was 
73.2 ± 19.5. The quality of life of our patients seems to be slightly higher than in other 
mentioned groups. In a recent German QLQ-30 questionnaire study in more than 100 
cases of cystectomy, the global health status/quality of life score for patients 
underwent cystectomy and neobladder formation according to Hautmann were (72.3 
± 19.5) while for those underwent cystectomy and ileal conduit it was (58.0 ± 25.3 ( 
with the difference to be statistically significant139. In another Japanese group the 
global health status/quality of life score for patients underwent cystectomy and 
ortotopic diversions was also 72140. QLQ-BLM 30 was used in our study as bladder 
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cancer–specific questionnaire specific for muscle invasive bladder cancer patients 
undergoing cystectomy and urinary diversion because this type of questionnaire was 
recently validated in some studies. In the German study139 applying the Hautmann 
pouch as diversion for their cystectomy patients the mean score of the urinary 
symptoms was 33.6 ± 26.3 while our mean score was 32.2 ± 20.2 which is slightly 
lower keeping in mind that a higher score indicates a worse symptomatology. 
The five questions concerning bowel habits from the Gastrointestinal Quality of 
Life Index (GIQLI) were used to evaluate the change that occurred due to the 
operation. This questionnaire was used for the first time by Fung and his colleges93. 
They found that there was no change in the bowel habits preoperatively and for 2 
years follow up in patients undergoing the Studer ileal neobladder as the type of 
diversion after cystectomy. In our series the median change of bowel habits pre and 
postoperatively was 0. Therefore we can assume that the technique of the I pouch 
neobladder by using only 40 cm from the intestine has no negative impact on bowel 
habits postoperatively. 
 
4.6 Sexual function: 
RC may be associated with sexual dysfunction in both men and women. 
Erectile impairment in males after RC is more extensively described in the literature 
than female sexual dysfunction141,142. 
For men, even when the operation is performed by skilled and experienced 
surgeons after meticulous nerve sparing dissection, preservation of normal sexual 
function is only 50%134. Preservation of the whole or part of the prostate and/or 
seminal vesicles has been proposed to attain a higher potency rate of 75% to 
100%143. However the problems with such procedures are increased recurrence rate 
and chronic urinary retention rate, probably related to prostatic remnants. Moreover, 
the risk of prostate cancer remains unchanged144. 
This type of surgery should be done only in specially selected patients who are 
relatively young, sexually active with organ-confined bladder tumour without high risk 
of subsequent urethral recurrence30. All aspects of female sexuality may remain 
unchanged following cystectomy and ileal neobladder formation as long as sexual 
activity is not ceased due to other reasons142. The functional length of the vagina is 
probably less important, although an intraoperative length of >12 cm measured 
during surgery has been. Retubularisation of the vagina done in a longitudinal 
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fashion can cause dyspareunia if it results in lumen narrowing; hence, closing the 
vagina transversely might be more appropriate145. Only half of female patients have 
successful sexual intercourse after RC; factors that might attribute to this are reduced 
vaginal lubrication caused by damage to autonomic nerves originating from the 
hypogastric plexus, inability to have orgasms, decreased sexual desire, and 
dyspareunia142. Another small study has compared nerve sparing and non–nerve-
sparing cystectomy in females and found that preservation of female sexual function 
was more pronounced in patients who received neurovascular preservation 
surgery146. 
Regarding the sexual function in the group of patents with answered 
questionnaire 63.6% (69.2% for men and 42.9% for women) of our patients remained 
sexually active postoperatively while 26.4% lost their sexual function. A larger study 
with 101 male patients reporting potency rate of 62% in men 49 years and 
younger147. In a larger group of patients with 20 years of follow up an overall potency 
rate of 37.8% was reported86. Recently a Japanese group showed that most of their 
patients (88%) had lost sexual function after radical cystectomy and orthotopic 
neobladder148. The Ulm group reported that 58.6% of their female patients remained 
sexually active postoperatively. In view of these results, our results show that a high 
percent of our patients retain their sexual function postoperatively. 
 
4.7 Urodynamics: 
An intact sphincteric mechanism, adequate bladder capacity, absence of 
uninhibited contractions and good compliance are the main features determining the 
neobladder function and continence. 
The importance of studying the urodynamic characters of orthotopic reservoirs 
is that the volitional voiding via the urethra and continence are considered the most 
important factors determining a good quality of life for these patients149. 
In a study comparing three different neobladders using different parts of the 
intestine (ileal, ileocecal and sigmoid) urodynamicaly, they found no significant 
differences between them regarding the maximal capacity and the neobladder 
volume, the pressure at the maximal capacity, the pressure at maximal flow, the post 
void residual and the maximal flow150. 
 For the urodynamically analyzed group of our patients, cystometric capacity 
was 445.4 ± 86.5 ml. (median 455, range 300-590). In a study evaluating urodynamic 
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characters of asymptomatic males the mean cystometric capacity was 329 ± 15 
ml151. By contrast the median cystometric capacity of the 60 cm ileal Hautmann 
neobladder was 480 ml (370–806)152. .A Turkish group evaluated the Hautmann 
pouch after modifying the length of the bowel to 40 cm only, the neobladder capacity 
of their patients reach to 330 ml after 6 months and to 550 ml after 18 months of 
follow up153. The Studer pouch using 60 cm from the bowel but only 40 cm for the 
pouch itself showed a cystometric capacity of 420 ml after a follow up of about 5 
years154. The PADUA pouch (40 cm from bowel shaped to a reservoir in an inner 
circle manner) was evaluated urodynamically 1 and 4 years after cystectomy. The 4 
years cystometric capacity was reported to be 544 ± 95 ml149. 
Theoretically, making the reservoir from a larger segment of bowel, e.g. 60 cm 
appears to be a good solution, as with a 50% increase in bowel surface almost 
double the capacity can be obtained. Initially results do appear better with longer 
micturition intervals and better postoperative continence. However, the advantage is 
only temporary and a floppy bag may develop with increased risk of chronically 
infected residual urine and high risk for lifelong intermittent self-catheterisation74.  
These findings showed that the I pouch using only 40 cm from the intestine 
has a very good capacity in comparison to normal population or other types of ileal 
orthotopic diversions and that the use of smaller length from ileum has no obvious 
effect on the final capacity in the long term period. In the Hautmann pouch the 
median residual volume was 10 ml, 15 ml for the Studer pouch and 50 ml for the 
PADUA pouch149,152,154. The mean residual volume for the study group of our patients 
was 28 ± 53 ml. This makes the functional capacity (cystometric capacity- residual 
urine) of our neobladder of about 420 ml. Moreover the rate of CIC usage was only 
2.1 % which is considerably lower than that of other techniques with 7% for Studer 
and 5.6 % for the Hautmann reservoir86,90.  
Compliance describes the change in volume over a related change in reservoir 
pressure. During normal filling of the intestinal reservoir little or no pressure changes 
occurs to have a normal or low compliant pouch. There is no standard for what is 
normal, low or high compliance155. 
The mean end filling pressure of the I pouch was 19 ± 7.9 cmH2O while the 
median for the Hautmann pouch was 16, 26 for the modified Hautmann pouch and 
18 for the PADUA and Studer pouches90,153. In view of these results the urodynamic 
parameters of the I pouch are comparable to other orthoptopic neobladders. 
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Limitations of this study include the relatively small sample size, the relatively 
short follow up time, the continence rates depend on questionnaire analysis with 
subsequent effect from subjectivity. However many Items were in favour of the I 
pouch as the use of only 40 cm of the bowel, the low obstruction and reflux rates, the 
low rate of the CIC use, the satisfactory neobladder capacity  and the relatively high 
quality of life. 
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5. Conclusion 
Based on the results of this interim analysis, the functional, oncological and 
perioperative outcomes of the “I-pouch” neobladder technique are comparable to 
other established ileal neobladder techniques. Although using an antireflux technique 
of ureteral implantation, the ureterointestinal stenosis rate is only 2 %. Even though 
we use only 40 cm from the terminal ileum to create the pouch, the final neobladder 
capacity are comparable to those using longer bowel segment.  
The quality of life of patients with I pouch is good reaching in some cases the 
quality of life of the normal population. In addition, the differences to other ileal 
reservoirs are that the length of ileum is reduced to 40 cm with subsequent less 
complication on the gastrointestinal tract and that the directly implanted ureters lie on 
the dorsal wall of the pouch which facilitates instrumentation of the upper tract at a 
later point. Further prospective randomized controlled studies are needed to compare 
the results of I pouch to other types of orthotopic diversions to know if there is one 
type is superior to the others. However this will be hardly to prove. 
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6. Summary 
There are many factors affect the choice of the urinary diversion after 
cystectomy which are either cancer-related or patient-related.  Orthotopic diversion is 
the preferred urinary shunt whenever possible and ilieum is the most used part of the 
bowel. There are many types of neobladders that were developed in an attempt to 
reach a perfect solution for urinary diversion. A newly developed neobladder by 
Department of Urology in Tübingen (the “I pouch”) was extensively studied in this 
thesis regarding the perioperative, functional and oncological outcomes. 
In this study 97 patients that underwent radical cystectomy and I pouch as a 
urinary diversion between January 1999 until August 2011 were included. All 
preoperative and postoperative parameters were recorded as age, sex, serum 
creatinine, pathology of the tumor, presence of metastasis and complications in 
which we used a special grading system (Clavien grading) to categorize 
complications and to be better compared with other techniques in literature. The 
follow up of these patients reach more than 40 month. The presence and absence of 
recurrence was also recorded and the survival rates of the patients. All alive patients 
were contacted to do questionnaires evaluating the quality of life after the operation 
and more than one third of the patients answered them. The used questionnaires 
were the (SF-36) as general questionnaire, the (QLQ-C30 version 3) as a cancer-
specific questionnaire, the (QLQ-BLM30) as disease specific for invasive bladder 
cancer, 5 questions from the Gastrointestinal Quality of Life Index to asses the bowel 
habits changes after the operation and a specific self developed questionnaire of the 
department to evaluate the items thought to be missed by the other questionnaires. 
Moreover 10 patients accepted to do follow up urodynamic study which was done to 
evaluate objectively parameters as cystometric capacity of the newly formed bladder, 
the pressure inside the pouch during filling and during evacuation, the uroflow, the 
urethral closing pressure and the presence or absence of postmicturition residual 
urine. 
It appears that neither the I pouch nor any other pouch has clear superiority 
over the other types. Each type has advantages and disadvantages. The advantages 
of the I pouch that it uses only 40 cm from the ileum with no effect on the final 
capacity of the pouch reaching about 450 ml. Although an antireflux technique of 
ureter reimplantaion was used, this did not increase the upper urinary tract 
obstruction rate which was only (2.1 %) that was even smaller than other orthotopic 
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neobadders using a refluxing mechanism oh ureter implantation as Studer and 
Hautmann pouches. Indeed the rate of reflux was only 1% which helps in avoiding 
deterioration of the renal function. The bowel habits in patients with I pouch were not 
affected. The sexual function was preserved in about 64 % of our patients after the 
operation which is considered high rate in comparison with other series in the 
literature. The quality of life of patients with I pouch is good reaching in some cases 
the quality of life range of the normal population. The disadvantage  of the I pouch is 
the some what low continence rates specially at the day time which can not be 
explained in terms of low capacity.  
The perioperative, oncological and functional outcomes of the I pouch are 
comparable to other well known established techniques like the Studer, Hautmann, 
Mansoura and T pouches. 
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SF-36  
1. In der Regel würden Sie sagen, Ihre Gesundheit ist: 
 
a) Gut (1) 
b) Sehr gut (2) 
c) Gut (3) 
d) Mäßig (4) 
e) Mangelhaft (5) 
 
2. Im Vergleich zu vor einem Jahr, wie würden Sie Ihrem Gesundheit 
im Allgemeinen jetzt beurteilen? 
 
a) Jetzt viel besser als vor einem Jahr (1) 
b) Etwas besser jetzt als vor einem Jahr (2) 
c) Ungefähr die gleiche (3) 
d) Etwas schlechter als vor einem Jahr (4) 
e) Viel schlimmer als vor einem Jahr (5) 
 
Die folgenden Punkte handeln von Aktivitäten, die Sie während eines 
typischen Tages tun könnten. Begrenzt Sie Ihre Gesundheit bei der 
Ausübung dieser Aktivitäten? Wenn ja, wie viel? 
 
3. Kräftige Aktivitäten, wie Laufen, Heben schwerer Objekte, die 
Teilnahme an anstrengenden Sport 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
4. Mäßige Aktivitäten, wie das Verschieben eines Tisch und das 
Schieben eines Staubsaugers, Bowling oder Golf spielen 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
5. Heben oder Tragen von Lebensmitteln 
 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
6. Treppensteigen (mehrere Stockwerke) 
 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
  
7. Treppensteigen (ein Stockwerk) 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
8. Sich biegen, knien, oder sich bücken 
 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
9. Gehen mehr als eine Meile (ca. 1.7km) 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
10. Gehen um mehrere Wohnblöcke 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
11. Gehen um einen einzigen einem Block 
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
12. Baden oder sich selbst Anziehen  
 
a) Ja, starke Einschränkung (1) 
b) Ja, aber nur geringe Einschränkung (2) 
c) Nein, überhaupt nicht eingeschränkt (3) 
 
In den letzten 4 Wochen hatten Sie eine der folgenden Schwierigkeiten bei 
Ihrer Arbeit oder anderen alltäglichen Tätigkeiten als Ergebnis Ihrer 
körperlichen Gesundheit? 
 
13. Sie haben die Menge der Zeit reduziert, die Sie für Ihre Arbeit oder 
andere Aktivitäten verbracht haben 
 
a) Ja 
b) Nein 
 
14. Sie haben weniger erzielt als Sie erreichen wollten 
 
  
a) Ja 
b) Nein 
 
15. Sie waren in der Art der Arbeit oder anderen Tätigkeiten beschränkt 
 
a) Ja 
b) Nein 
 
16. Sie hatten Schwierigkeiten bei der Ausführung der Arbeit oder 
anderen Tätigkeiten (zum Beispiel war es mit einem zusätzlichen  
Aufwand verbunden) 
 
a) Ja 
b) Nein 
 
 
Während der letzten 4 Wochen hatten Sie eine der folgenden 
Schwierigkeiten bei Ihrer Arbeit oder anderen alltäglichen Tätigkeiten als 
Folge von emotionalen Problemen (wie z. B. deprimiert oder ängstlich 
sein)? 
 
17. Sie haben die Menge der Zeit reduziert, die Sie für Ihre Arbeit oder 
andere Aktivitäten verbracht haben 
 
a) JA 
b) Nein 
 
18. Sie haben weniger erzielt als Sie erreichen wollten 
 
a) JA 
b) Nein 
 
19. Sie hatten Schwierigkeiten bei der Ausführung der Arbeit oder 
anderen Tätigkeiten (zum Beispiel war es mit einem zusätzlichen  
Aufwand verbunden) 
a) JA 
b) Nein 
 
20. In den letzten 4 Wochen, in welchem Umfang hat Ihre körperliche 
Gesundheit oder emotionale Probleme ihre üblichen normalen 
sozialen Aktivitäten mit Familie, Freunden, Nachbarn oder Gruppen 
beeinträchtigt? 
 
a) Überhaupt nicht (1) 
b) Leicht (2) 
c) Mäßig (3) 
d) Ganz ein bisschen (4) 
e) Extrem (5) 
  
21. Wie ausgeprägt waren ihre körperliche Schmerzen während der 
letzten 4 Wochen? 
 
a) Keine (1) 
b) Ganz leicht (2) 
c) Leicht (3) 
d) Mäßig (4) 
e) Stark (5) 
f) Sehr stark (6) 
 
22. Wie stark haben in den letzten 4 Wochen ihre Schmerz Sie bei der 
Ausübung Ihrer normalen Arbeit (einschließlich der Arbeit 
außerhalb des Hauses und Hausarbeit) beeinträchtigt? 
 
a) Überhaupt nicht (1) 
b) Leicht (2) 
c) Mäßig (3) 
d) Ziemlich stark (4) 
e) Extrem (5) 
 
Diese Fragen handeln darüber, wie Sie sich in den letzten 4 Wochen fühlen 
und wie es um Sie stand. Für jede Frage, kreuzen Sie bitte nur eine Antwort 
an, die die Art und Weise wie  Sie sich gefühlt haben, am genauesten 
wiedergibt. 
 
23. Hatten Sie das Gefühl voller Elan zu sein? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück während dieser Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
24. Waren Sie sehr nervös? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
25. Haben Sie sich so niedergeschlagen gefühlt, dass Sie nichts aufheitern 
konnte? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
  
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
26. Haben Sie ruhig und gelassen gefühlt? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
27. Hatten Sie viel Energie? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
28. Fühlten Sie sich niedergeschlagen und deprimiert? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
29. Fühlten Sie sich erschöpft? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
30. Haben Sie sich glücklicher gefühlt? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
31. Fühlten Sie sich müde? 
  
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2) 
c) Ein gutes Stück von der Zeit (3) 
d) Etwas während dieser Zeit (4) 
e) Ein wenig während dieser Zeit (5) 
f) Nicht während dieser Zeit (6) 
 
32. In den letzten 4 Wochen, wie viel Zeit haben sich Ihre körperliche 
Gesundheit oder emotionale Probleme mit Ihrem sozialen Aktivitäten 
(z.B. Besuche bei Freunden, Verwandten, etc.) beeinträchtigt? 
 
a) Die ganze Zeit (1) 
b) Die meiste Zeit (2)  
c) Einiges währen dieser Zeit (3) 
d) Ein wenig während dieser Zeit (4) 
 
Wie richtig oder falsch ist jede der folgenden Aussagen für Sie? 
 
33. Ich glaube, dass ich leichter krank werde als andere Menschen. 
 
 
 
a) Stimmt definitiv (1) 
b) Stimmt meistens (2) 
c) Sie wissen nicht (3) 
d) Stimmt meistens nicht (4) 
e) Stimmt definitiv nicht (5) 
 
34. Ich bin so gesund wie jeder den ich kenne. 
 
 
a) Stimmt definitiv (1) 
b) Stimmt meistens (2) 
c) Sie wissen nicht (3) 
d) Stimmt meistens nicht (4) 
e) Stimmt definitiv nicht (5) 
 
35. Ich erwarte, dass sich mein gesundheitlicher Zustand noch 
verschlechtern wird. 
 
 
a) Stimmt definitiv (1) 
b) Stimmt meistens (2) 
c) Sie wissen nicht (3) 
d) Stimmt meistens nicht (4) 
e) Stimmt definitiv nicht (5) 
 
36. Meine Gesundheit ist hervorragend. 
 
 
  
a) Stimmt definitiv (1) 
b) Stimmt meistens (2) 
c) Sie wissen nicht (3) 
d) Stimmt meistens nicht (4) 
e) Stimmt definitiv nicht (5) 
 
  
Sehr geehrte(r) Patient(in), 
 
für die folgenden Fragen möchten wir Sie bitten, sie so zu beantworten, wie Sie sich 
damals unmittelbar 2 Wochen vor der grossen Blasenoperation (radikale 
Zystektomie) von Seiten ihrer Stuhlgangsgewohnheiten gefühlt haben. 
 
Q1. Wie oft in den letzten 2 Wochen fühlten Sie sich durch die Häufigkeit des 
Stuhlganges belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q2. Wie oft in den letzten 2 Wochen fühlten Sie sich durch die dranghaftliche 
Stuhlbewegungen belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q3. Wie oft in den letzten 2 Wochen fühlten Sie sich durch einen Durchfall belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q4. Wie oft in den letzten 2 Wochen fühlten Sie sich durch Verstopfung belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q5. Wie oft in den letzten 2 Wochen fühlten Sie sich durch unkontrollierten 
Stuhlgangsverlust (Stuhlinkontinenz) belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
  
Sehr geehrte(r) Patient(in), 
 
für die folgenden Fragen möchten wir Sie bitten, sie so zu beantworten, wie Sie sich 
in den letzten 2 Wochen von Seiten ihrer Stuhlgangsgewohnheiten gefühlt haben. 
 
 
 
Q1. Wie oft in den letzten 2 Wochen fühlten Sie sich durch die Häufigkeit des 
Stuhlganges belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q2. Wie oft in den letzten 2 Wochen fühlten Sie sich durch die dranghaftliche 
Stuhlbewegungen belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q3. Wie oft in den letzten 2 Wochen fühlten Sie sich durch einen Durchfall belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q4. Wie oft in den letzten 2 Wochen fühlten Sie sich durch Verstopfung belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
Q5. Wie oft in den letzten 2 Wochen fühlten Sie sich durch unkontrollierten 
Stuhlgangsverlust (Stuhlinkontinenz) belästigt? 
Die ganze Zeit (0), die meiste Zeit (1), manchmal (2), selten (3), nie (4) 
 
  
SPEZIFISCHER FRAGEBOGEN FÜR PATIENTEN MIT NEOBLASE 
 
 
1. Nehmen Sie Vitamin B12 Präparate ein? 
a) Ja 
b) Nein 
2. Nehmen Sie Natrium-Bikarbonat (Na HCO3) ein (z.B. Bicanorm® , 
Nephrotrans ®)?  
a) Ja 
b) Nein 
3. Wie viele Harnwegsinfektionen hatten Sie im letzten Jahr? 
A) 1                    B) 2                     C) 3                   D) 4                    E) > 4 
4. Wenn ja, waren diese Harnwegsinfektionen fieberhaft? 
a) Ja   
b) Nein 
5. Wie viel ml Liter urinieren Sie im Durchschnitt ungefähr (grober 
Schätzwert)? 
A) <100 ml    
B) 100-200 ml   
C) 200-300 ml 
D) 300-400 ml 
E) 400-500 ml   
F) >500 ml   
 
6. Müssen Sie beim Wasserlassen die Bauchpresse betätigen, damit die 
Neoblase entleert werden kann? 
A) ja        B) Nein 
7.  Benutzen Sie Katheter um die Blase zu entleeren? 
A) ja        B) Nein 
8. Wenn ja, wie oft pro 24 Studen führen Sie einen Einmalkatheterismus 
durch? 
Anzahl tagsüber:…….         Anzahl nachts:…… 
Kathetervolumen tagsüber:…….          Kathetervolumen nachts:……
  
  
 
9. Verspüren Sie Schmerzen über den Nieren während des Wasserlassens? 
A) ja        B) Nein 
 
10. Benutzen Sie Vorlagen? 
Tagsüber  
A) Ja        B) Nein 
Wenn Ja, wie viele?  
………………. 
 
Sind Vorlagen tagsüber feucht oder naß? 
 A) feucht   B) naß 
 
Verwenden Sie die Vorlage(n) lediglich als „Sicherheitsvorlage“? 
 A) Ja    B) Nein 
 
Angenommen es kommt zum Urinverlust in die Vorlage tagsüber. Wenn Sie 
nun Ihre Vorlage wiegen, um wie viel Gramm ist diese hiernach schwerer? 
(Gewicht feuchte/nasse Vorlage  minus  Gewicht trockene Vorlage) 
………………..g 
 
Nachts 
A) Ja        B) Nein 
Wenn Ja, wie viele?  
………………. 
 
Sind die Vorlagen nachts feucht oder naß? 
 A) feucht   B) naß 
 
Verwenden Sie die Vorlage(n) lediglich als „Sicherheitsvorlage“? 
 A) Ja    B) Nein 
 
 
  
Angenommen es kommt zum Urinverlust in die Vorlage nachts. Wenn Sie nun 
Ihre Vorlage wiegen, um wie viel Gramm ist diese hiernach schwerer? 
(Gewicht feuchte/nasse Vorlage  minus  Gewicht trockene Vorlage) 
………………..g 
 
11. Für männliche Patienten: Benutzen Sie eine Kondomurinal?  
A) Ja        B) Nein 
 
12. Merken Sie, dass sich in der Neoblase Schleim bildet?  
A) Ja    B) Nein  C) Bin mir nicht sicher 
 
13.  Bei Männern: Haben Sie vor der radikalen Zystektomie Präparate zur 
Steigerung der erektile Funktion (Gliedsteife) eingenommen (z.B. Viagra 
®, Cialis ®, Levitra ®)?  
A) Ja        B) Nein 
 
 
14. Bei Männern: Nehmen Sie derzeit Präparate zur Steigerung der erektile 
Funktion (Gliedsteife) ein (z.B. Viagra ®, Cialis ®, Levitra ®) ?  
A) Ja        B) Nein  
 
 
 
 
 
 
 
 
 
